



# Model List of Essential Medicines

## BCG vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against tuberculosis

## Japanese encephalitis vaccine

Section	Indications
Recommendations for certain regions All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

## Medicines for COVID-19

Section	Indications
Medicines for COVID-19 Refer to WHO living guidelines	COVID-19

## Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

## Acetazolamide

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines Oral > Solid: 250 mg	Primary open-angle glaucoma

## Acetic acid

Section	Indications
Ear, nose and throat medicines [c] Local > Otological > drops: 2% in alcohol	Infectious diseases of external ear

## Acetylcysteine

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule Oral > Liquid: 10%; 20%	Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs Acute or subacute hepatic failure

## Acetylsalicylic acid

Section	Indications
Antimigraine medicines > For treatment of acute attack Oral > Solid: 300 to 500 mg	Migraine
Anti-platelet medicines Oral > Solid: 100 mg	Acute myocardial infarction Cerebral ischaemic stroke
Medicines for juvenile joint diseases Oral > Solid: 100 to 500 mg Local > Rectal > Suppository: 50 to 150 mg	Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) Oral > Solid: 100 to 500 mg Local > Rectal > Suppository: 50 to 150 mg	Pain

## Aciclovir

Section	Indications
Antiherpes medicines	Zoster
Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)	Varicella
Oral > Liquid: 200 mg per 5 mL	Herpes simplex infections
Oral > Solid: 200 mg tablet	
Ophthalmological preparations > Anti-infective agents	Herpes simplex keratitis
Local > Ophthalmological > Ointment: 3% w/w	

## Aclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

## Activated charcoal

Section	Indications
Antidotes and other substances used in poisonings > Non-specific Oral > Other: powder	Unspecified injury, poisoning or certain other consequences of external causes

## Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
Medicines for juvenile joint diseases Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Juvenile idiopathic arthritis

## Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

## Albendazole

Section	Indications
<b>Intestinal anthelmintics</b> Oral > Solid > tablet: 400 mg (chewable, scored)	Echinococcosis
Oral > Solid > tablet: 400 mg (chewable, scored))	Ascariasis
	Enterobiasis
	Trichuriasis
	Hookworm diseases
	Cysticercosis
<b>Cysticidal medicines</b> Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	Other specified echinococcosis
	Cysticercosis of central nervous system
<b>Antifilarials</b> Oral > Solid > tablet: 400 mg (chewable, scored)	Filariasis

## Alcohol based hand rub

Section	Indications
<b>Disinfectants</b> Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol	Denatured alcohol

## Alcuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)	Muscle relaxants

## All-trans retinoic acid

Section	Indications
<b>Targeted therapies</b> Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

## Allopurinol

Section	Indications
<b>Medicines used to treat gout</b> Oral > Solid: 100 mg	Gout
<b>Supportive medicines</b> Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

## Alteplase

Section	Indications
Thrombolytic medicines Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection	Cerebral ischaemic stroke

## Amidotrizoate

Section	Indications
Diagnostic agents > Radiocontrast media Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)	Amidotrizoate

## Amikacin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin for Other specified conjunctivitis
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Therapeutic equivalent to gentamicin for Infectious blepharitis
	First choice co-prescribed with cefotaxime Acute pyelonephritis (severe)
	co-prescribed with ceftriaxone Acute pyelonephritis (severe)
	Second choice co-prescribed with cloxacillin Sepsis without septic shock
Antituberculosis medicines Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant Mycobacterium tuberculosis

## Amiloride

Section	Indications
Diuretics Oral > Solid: 5 mg (hydrochloride)	Oedema Ascites

## Amiodarone

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)  Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)	Cardiac arrhythmia

## Amitriptyline

Section	Indications
Medicines for other common symptoms in palliative care Oral > Solid: 25 mg; 10 mg; 75 mg	Palliative care

## Amlodipine

Section	Indications
Antihypertensive medicines Oral > Solid: 5 mg (as maleate, mesylate or besylate)	Essential hypertension

## Amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)	Malaria due to Plasmodium falciparum
	Malaria due to Plasmodium vivax

## Amodiaquine + sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package	Malaria

## Amoxicillin

Section	Indications
<b>Access group antibiotics</b>	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	<b>First choice</b>  Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet	co-prescribed with gentamicin  Sepsis without septic shock
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid	
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)	
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection	<b>Other indications</b>  Bacterial infection of unspecified site  Infectious cystitis

## Amoxicillin + clavulanic acid

Section	Indications
<b>Access group antibiotics</b>	
Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection	<b>First choice</b>  Infectious cystitis  Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)	
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid	
Oral > Solid: 500 mg + 125 mg tablet	<b>Other indications</b>  Bacterial infection of unspecified site
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid	
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)	
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)	
<b>Antituberculosis medicines</b>	
Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)	

## Amphotericin B

Section	Indications
<p><b>Antifungal medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)</p>	<p>Blastomycosis</p> <p>Aspergillosis</p> <p>Cryptococcosis</p> <p>Candidosis</p> <p>Coccidioidomycosis</p> <p>Histoplasmosis</p> <p>Sporotrichosis</p>
<p><b>Antileishmaniasis medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)</p>	<p>Visceral leishmaniasis</p>

## Ampicillin

Section	Indications
<p><b>Access group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection</p> <p>Oral &gt; Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension</p> <p>Oral &gt; Solid: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p><b>First choice</b></p> <p>co-prescribed with <b>gentamicin</b></p> <p>Peritoneal abscess (severe)</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Sepsis without septic shock</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Peritonitis (severe)</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children]</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Peritonitis (mild-moderate)</p> <p>co-prescribed with <b>gentamicin</b></p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</p> <p><b>Second choice</b></p> <p>Bacterial meningitis</p> <p><b>Other indications</b></p> <p>Bacterial infection of unspecified site</p>

## Anastrozole

Section	Indications
Hormones and antihormones Oral > Solid: 1 mg tablet	Other specified malignant neoplasms of breast Malignant neoplasms of breast

## Anidulafungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to <b>micafungin</b> for <b>Systemic or invasive candidosis</b>

## Ansuvimab

Section	Indications
Medicines for Ebola virus disease Parenteral > General injections > IV: 400 mg powder for injection	<b>Ebola virus disease</b>

## Anti-d immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 250 µg in single-dose vial Parenteral > General injections > IM: 250 µg in single-dose vial	<b>Maternal care for red cell antibodies</b> <b>Rh incompatibility reaction</b>

## Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 150 IU per mL in vial Parenteral > Locoregional injections > Other: 150 IU per mL in vial	<b>Rabies</b>

## Anti-rabies virus monoclonal antibodies

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)	<b>Rabies</b>

## Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 500 IU in vial	Tetanus

## Antirabies hyperimmune serum

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule	Rabies

## Antivenom immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Antivenom sera

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for  Vinous thromboembolism  Therapeutic equivalent to dabigatran for  Other specified atrial fibrillation

## Aprepitant

Section	Indications
Antiemetic medicines Oral > Liquid: 125 mg powder for oral suspension (in sachet) Oral > Solid: 80 mg; 125 mg; 165 mg	Nausea or vomiting

## Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

## Artemether

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Artemether + lumefantrine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Artesunate

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution Oral > Solid: 50 mg tablet Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Artesunate + amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Artesunate + mefloquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Artesunate + pyronaridine tetraphosphate

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules	Malaria due to <i>Plasmodium falciparum</i> Malaria due to <i>Plasmodium vivax</i>

## Ascorbic acid

Section	Indications
Vitamins and minerals Oral > Solid: 50 mg	Scurvy

## Asparaginase

Section	Indications
Cytotoxic medicines Powder for injection: 10 000 IU in vial.	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

## Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atenolol

Section	Indications
Antiangular medicines Oral > Solid: 50 mg; 100 mg	Angina pectoris
Antihypertensive medicines Oral > Solid: 50 mg; 100 mg	Essential hypertension Therapeutic equivalent to bisoprolol for Essential hypertension

## Atezolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung

## Atoltivimab + maftivimab + odesivimab

Section	Indications
Medicines for Ebola virus disease Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial	Ebola virus disease

## Atorvastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia
	Therapeutic equivalent to simvastatin for Coronary atherosclerosis

## Atracurium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 10 mg per mL (besylate)	Muscle relaxants

## Atropine

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)	Exposure to or harmful effects of undetermined intent of pesticides
Preoperative medication and sedation for short-term procedures Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)	Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide for Cycloplegic drug
Ophthalmological preparations > Mydriatics Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)	Anterior uveitis

## Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines Cell suspension for infusion: $2 \times 10^6$ anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

## Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

## Azathioprine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 50 mg	Rheumatoid arthritis, serology unspecified Psoriatic arthritis
Immunomodulators for non-malignant disease Oral > Solid: 50 mg	Relapsing-remitting multiple sclerosis
Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)	Failure or rejection of transplanted organs or tissues
Oral > Liquid: 10 mg per mL Oral > Solid > tablet: 50 mg (scored); 25 mg	

## Azithromycin

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Solution (eye drops): 1.5% eye drops	Trachoma
Watch group antibiotics	First choice co-prescribed with ceftriaxone
Oral > Liquid: 200 mg per 5 mL oral liquid	Gonococcal infection
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule	Second choice co-prescribed with cefixime
	Gonococcal infection

## Aztreonam

Section	Indications
Reserve group antibiotics Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified bacterial diseases

## Barium sulfate

Section	Indications
Diagnostic agents > Radiocontrast media Oral > Liquid: Aqueous suspension	Barium sulfate with suspending agents

## Beclometasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)	Therapeutic equivalent to budesonide for  Asthma  Asthma

## Beclometasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol for  Asthma

## Bedaquiline

Section	Indications
Antituberculosis medicines Oral > Solid: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

## Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma  Follicular lymphoma

## Benzathine benzylpenicillin

Section	Indications
Access group antibiotics  Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)	First choice  Syphilis  Congenital syphilis [children]
	Other indications  Bacterial infection of unspecified site

## Benznidazole

Section	Indications
American trypanosomiasis  Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg	Chagas disease

## Benzoic acid + salicylic acid

Section	Indications
Dermatological medicines > Antifungal medicines  Local > Topical > Cream: 6% + 3%  Local > Topical > Ointment: 6% + 3%	Fungal infection of the skin

## Benzoyl peroxide

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation  Local > Topical > Cream: 5%  Local > Topical > Lotion: 5%	Acne

## Benzyl benzoate

Section	Indications
Dermatological medicines > Scabicides and pediculicides  Local > Topical > Lotion: 25%	Pthiriasis  Pediculosis corporis  Pediculosis capitis  Scabies

## Benzylpenicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	First choice Congenital syphilis [children] Syphilis co-prescribed with gentamicin
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	Sepsis without septic shock co-prescribed with gentamicin
	Acute malnutrition in infants, children or adolescents (complicated) [children]
	co-prescribed with gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choice
	Bacterial meningitis
	Other indications
	Bacterial infection of unspecified site

## Betamethasone

Section	Indications
Dermatological medicines > Anti-inflammatory and antipruritic medicines	
Local > Topical > Cream: 0.1% (as valerate)	Pruritus due to skin disorder
Local > Topical > Ointment: 0.1% (as valerate)	Psoriasis of unspecified type
	Dermatitis or eczema
	Lichen planus

## Bevacizumab

Section	Indications
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations	Age related macular degeneration
Parenteral > Locoregional injections > Intravitreal: 25 mg per mL	

## Bicalutamide

Section	Indications
Hormones and antihormones	
Oral > Solid: 50 mg	Malignant neoplasms of prostate

## Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to <a href="#">trametinib</a> for <a href="#">Other specified melanoma of skin</a>

## Biperiden

Section	Indications
Medicines for parkinsonism Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate) Oral > Solid: 2 mg tablet (hydrochloride)	<a href="#">Parkinson disease</a>

## Bisacodyl

Section	Indications
Laxatives	Therapeutic equivalent to <a href="#">senna</a> for <a href="#">Constipation</a>

## Bisoprolol

Section	Indications
Antianginal medicines Oral > Solid: 1.25 mg; 5 mg	<a href="#">Angina pectoris</a>
Medicines used in heart failure Oral > Solid: 1.25 mg; 5 mg	<a href="#">Heart failure</a>
Antihypertensive medicines Oral > Solid: 1.25 mg; 5 mg	<a href="#">Essential hypertension</a>
Antiarrhythmic medicines Oral > Solid: 1.25 mg; 5 mg	<a href="#">Cardiac arrhythmia</a>

## Bleomycin

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)	Kaposi sarcoma of unspecified primary site
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Hodgkin lymphoma
	Other specified malignant neoplasms of the ovary
	Germ cell tumour of testis

## Bortezomib

Section	Indications
Targeted therapies	Plasma cell myeloma
Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	

## Bromocriptine

Section	Indications
Antiseizure medicines	Parkinson disease
Oral > Solid: 2.5 mg; 5 mg	

## Budesonide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Asthma
Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose	
Ear, nose and throat medicines [c]	Allergic rhinitis
Local > Nasal > Spray: 100 µg per dose	

## Budesonide + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Asthma
Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose	

## Budesonide + salmeterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to <a href="#">budesonide + formoterol</a> for <a href="#">Asthma</a>

## Bumetanide

Section	Indications
Medicines used in heart failure	Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Heart failure</a>
Diuretics	Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Anuria or oliguria</a>
	Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Oedema</a>

## Bupivacaine

Section	Indications
<a href="#">Local anaesthetics</a> Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)	<a href="#">Local anaesthetics</a>

## Buprenorphine

Section	Indications
<a href="#">Medicines for opioid use disorders</a>	Therapeutic equivalent to <a href="#">methadone</a> for <a href="#">Opioid dependence</a>

## Bupropion

Section	Indications
<a href="#">Medicines for nicotine use disorders</a> Oral > Solid: 150 mg sustained-release (hydrochloride)	<a href="#">Nicotine dependence</a>

## C1 esterase inhibitor

Section	Indications
Plasma-derived medicines Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

## Cabergoline

Section	Indications
Antiseizure medicines Oral > Solid: 0.5 mg	Parkinson disease

## Caffeine citrate

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL) Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)	Apnoea of newborn

## Calamine

Section	Indications
Dermatological medicines > Anti-inflammatory and antipruritic medicines Local > Topical > Lotion:	Pruritus

## Calcipotriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Cream: 50 µg per mL (0.005%) Local > Topical > Lotion: 50 µg per mL (0.005%) Local > Topical > Ointment: 50 µg per mL (0.005%)	Psoriasis of unspecified type

## Calcitriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type

## Calcium

Section

Vitamins and minerals

Oral > Solid: 500 mg (elemental calcium)

Indications

Calcium deficiency

## Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Calcium gluconate

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Vitamins and minerals

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Hypermagnesaemia

Tetany due to acute calcium deficiency

## Canagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

## Capecitabine

Section

Cytotoxic medicines

Oral > Solid: 150 mg tablet; 500 mg tablet

Indications

Malignant neoplasms of colon

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

## Capreomycin

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

## Captopril

Section	Indications
Medicines used in heart failure Oral > Solid: 25 mg	Heart failure

## Carbachol

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines	Therapeutic equivalent to <i>pilocarpine</i> for  <i>Acute angle closure with pupillary block</i>
	Therapeutic equivalent to <i>pilocarpine</i> for  <i>Ocular hypertension</i>
	Therapeutic equivalent to <i>pilocarpine</i> for  <i>Primary open-angle glaucoma</i>

## Carbamazepine

Section	Indications
Antiseizure medicines Oral > Liquid: 100 mg per 5 mL  Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)	<i>Epilepsy or seizures</i>
Medicines for bipolar disorders Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg	<i>Bipolar or related disorders</i>

## Carbetocin

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	<i>Postpartum haemorrhage</i>

## Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines	Therapeutic equivalent to <a href="#">methimazole</a> for <a href="#">Thyrotoxicosis</a>

## Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	<a href="#">Other specified gliomas of brain</a> <a href="#">Other specified carcinomas of ovary</a> <a href="#">Retinoblastoma</a> <a href="#">Other specified malignant neoplasms of bronchus or lung</a> <a href="#">Malignant neoplasms of nasopharynx</a> <a href="#">Malignant neoplasms of kidney, except renal pelvis</a> <a href="#">Malignant neoplasms of breast</a> <a href="#">Osteosarcoma of bone and articular cartilage of unspecified sites</a> <a href="#">Malignant neoplasms of lip, oral cavity or pharynx</a> <a href="#">Malignant neoplasms of cervix uteri</a> <a href="#">Other specified malignant neoplasms of the ovary</a> <a href="#">Germ cell tumour of testis</a>

## Carvedilol

Section	Indications
Antianginal medicines	Therapeutic equivalent to <a href="#">bisoprolol</a> for <a href="#">Angina pectoris</a>
Medicines used in heart failure	Therapeutic equivalent to <a href="#">bisoprolol</a> for <a href="#">Heart failure</a>
Antihypertensive medicines	Therapeutic equivalent to <a href="#">bisoprolol</a> for <a href="#">Essential hypertension</a>
Antiarrhythmic medicines	Therapeutic equivalent to <a href="#">bisoprolol</a> for <a href="#">Cardiac arrhythmia</a>

## Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to <b>micafungin</b> for <b>Systemic or invasive candidosis</b>

## Cefalexin

Section	Indications
<b>Access group antibiotics</b>	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	<b>Second choice</b> <b>Chronic obstructive pulmonary disease with acute exacerbation</b>
Oral > Solid: 250 mg (as monohydrate)	<b>Other indications</b>
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	<b>Bacterial infection of unspecified site</b>

## Cefazolin

Section	Indications
<b>Access group antibiotics</b>	
Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	<b>First choice</b> <b>Other specified prophylactic measures</b> co-prescribed with <b>metronidazole</b> <b>Other specified prophylactic measures</b>
	<b>Second choice</b> <b>Osteomyelitis or osteitis</b>
	<b>Bacterial infection of joint</b>
	<b>Other indications</b>
	<b>Surgical site infection</b>

## Cefepime

Section	Indications
<b>Watch group antibiotics</b>	<b>Other specified bacterial diseases</b>

## Cefixime

Section	Indications
<p>Watch group antibiotics</p> <p>Oral &gt; Liquid: 100 mg per 5 mL powder for oral liquid</p> <p>Oral &gt; Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)</p>	<p>Second choice</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>co-prescribed with azithromycin</p> <p>Gonococcal infection</p>

## Cefotaxime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial powder for injection (as sodium salt)</p>	Bacterial infection of unspecified site

## Ceftaroline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection</p>	Other specified bacterial diseases

## Ceftazidime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection</p>	<p>First choice</p> <p>co-prescribed with vancomycin</p> <p>Endophthalmitis</p> <p>Other indications</p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p>

## Ceftazidime + avibactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 2 g in vial + 0.5 g in vial powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

## Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i>

## Ceftriaxone

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	First choice co-prescribed with metronidazole <b>Necrotising fasciitis</b>  Other indications <b>Bacterial infection of unspecified site</b>

## Cefuroxime

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	Second choice <b>Other specified prophylactic measures</b>

## Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for <b>Axial spondyloarthritis</b> Therapeutic equivalent to adalimumab for <b>Crohn disease site</b> Therapeutic equivalent to adalimumab for <b>Rheumatoid arthritis</b>
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for <b>Juvenile idiopathic arthritis</b>

## Cetirizine

Section	Indications
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to <b>loratadine</b> for <b>Allergic or hypersensitivity conditions of unspecified type</b>

## Chlorambucil

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Solid: 2 mg tablet	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Chloramphenicol

Section	Indications
Access group antibiotics	Bacterial infection of unspecified site
Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)	
Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection	
Oral > Liquid: 150 mg per 5 mL (as palmitate)	
Oral > Solid: 250 mg capsule	

## Chlorhexidine

Section	Indications
Medicines administered to the neonate [c]	Omphalitis of newborn
Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	
Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	
Antiseptics	Chlorhexidine
Local > Topical > Solution: 5% (digluconate) for dilution	

## **Chlorine base compound**

Section	Indications
<b>Disinfectants</b>	<b>Disinfectant, not elsewhere classified</b>
Local > Topical > Powder: 0.1% available chlorine for solution	
Local > Topical > Liquid: 0.1% available chlorine for solution	
Local > Topical > Solid: 0.1% available chlorine for solution	

## **Chloroquine**

Section	Indications
<b>Antimalarial medicines &gt; For chemoprevention</b>	<b>Malaria due to Plasmodium falciparum</b>
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)	<b>Malaria due to Plasmodium vivax</b>
Oral > Solid: 150 mg tablet (as phosphate or sulfate)	<b>Malaria due to Plasmodium ovale</b>
	<b>Malaria due to Plasmodium malariae</b>
<b>Antimalarial medicines &gt; For curative treatment</b>	<b>Malaria due to Plasmodium falciparum</b>
Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)	<b>Malaria due to Plasmodium vivax</b>
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)	
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)	
<b>Disease-modifying anti-rheumatic drugs (DMARDs)</b>	<b>Rheumatoid arthritis</b>
Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)	

## **Chlorothiazide**

Section	Indications
<b>Antihypertensive medicines</b>	Therapeutic equivalent to <b>hydrochlorothiazide</b> for <b>Essential hypertension</b>
<b>Medicines used in heart failure</b>	Therapeutic equivalent to <b>hydrochlorothiazide</b> for <b>Heart failure</b>

## **Chloroxylenol**

Section	Indications
<b>Disinfectants</b>	<b>Phenol disinfectant, not elsewhere classified</b>
Local > Topical > Solution: 4.8%	

## Chlortalidone

Section	Indications
Antihypertensive medicines	Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for <a href="#">Essential hypertension</a>
Medicines used in heart failure	Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for <a href="#">Heart failure</a>

## Chlortetracycline

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Other specified conjunctivitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Infectious keratitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Infectious blepharitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Trachoma</a>

## Cholera vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	<a href="#">Need for immunization against cholera alone</a>

## Ciclesonide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to <a href="#">budesonide</a> for <a href="#">Asthma</a>

## Ciclosporin

Section	Indications
<p>Immunomodulators for non-malignant disease</p> <p>Parenteral &gt; General injections &gt; IV: 50 mg per mL in 1 mL ampoule concentrate for injection</p> <p>Oral &gt; Liquid: 100 mg per mL</p> <p>Oral &gt; Solid &gt; capsule: 25 mg</p>	Failure or rejection of transplanted organs or tissues

## Cimetidine

Section	Indications
<p>Antiulcer medicines</p> <p>Oral &gt; Solid: 200 mg</p> <p>Parenteral &gt; General injections &gt; unspecified: 200 mg in 2 mL ampoule</p>	<p>Peptic ulcer, site unspecified</p> <p>Gastro-oesophageal reflux disease</p>

## Ciprofloxacin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 2 mg per mL (as hydrate)</p> <p>Oral &gt; Liquid: 250 mg per 5 mL (anhydrous)</p> <p>Oral &gt; Solid: 250 mg (as hydrochloride)</p> <p>Oral &gt; Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)</p>	<p>First choice</p> <p>Inflammatory and other diseases of prostate (mild to moderate)</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p> <p>Infectious diseases of external ear</p>
<p>Ear, nose and throat medicines [c]</p> <p>Local &gt; Otological &gt; drops: 0.3% (as hydrochloride)</p>	

## Cisplatin

Section	Indications
<p><b>Cytotoxic medicines</b></p> <p>Parenteral &gt; General injections &gt; unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection</p> <p>Parenteral &gt; General injections &gt; IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Malignant neoplasms of nasopharynx</p> <p>Germ cell tumour of testis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Malignant neoplasms of lip, oral cavity or pharynx</p> <p>Malignant neoplasms of cervix uteri</p>

## Cladribine

Section	Indications
<p><b>Medicines for multiple sclerosis</b></p> <p>Oral &gt; Solid &gt; tablet: 10 mg</p> <p><b>Cytotoxic medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial</p>	<p>Multiple sclerosis</p> <p>Langerhans cell histiocytosis</p>

## Clindamycin

Section	Indications
<p><b>Access group antibiotics</b></p> <p>Oral &gt; Liquid: 75 mg per 5 mL (as palmitate hydrochloride)</p> <p>Oral &gt; Solid: 150 mg (as hydrochloride) capsule</p> <p>Parenteral &gt; General injections &gt; unspecified: 150 mg per mL (as phosphate) injection</p>	<p>Bacterial infection of unspecified site</p>

## Clofazimine

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid: 100 mg; 50 mg</p> <p><b>Antileprosy medicines</b></p> <p>Oral &gt; Solid: 100 mg; 50 mg</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Leprosy</p>

## Clomifene

Section	Indications
Ovulation inducers Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

## Clomipramine

Section	Indications
Medicines for obsessive compulsive disorders Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)	Obsessive-compulsive disorder

## Clonazepam

Section	Indications
Antiseizure medicines Oral > Solid: 500 µg	Generalised myoclonic seizure

## Clopidogrel

Section	Indications
Anti-platelet medicines Oral > Solid: 75 mg; 300 mg	Acute ischaemic heart disease
	Presence of coronary angioplasty implant or graft

## Clotrimazole

Section	Indications
Antifungal medicines Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet	Vulvovaginal candidosis

## Cloxacillin

Section	Indications
Access group antibiotics Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	Bacterial infection of unspecified site

## Clozapine

Section	Indications
Medicines for psychotic disorders Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg	Schizophrenia or other primary psychotic disorders

## Coal tar

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Solution: 5%	Psoriasis of unspecified type

## Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to <a href="#">trametinib</a> for <a href="#">Other specified melanoma of skin</a>

## Codeine

Section	Indications
Opioid analgesics Oral > Solid: 30 mg tablet (codeine phosphate)	Pain
Antitussives Oral > Solid: 10 mg tablet (codeine phosphate)	Cough
Medicines for diarrhoea Oral > Solid: 30 mg tablet (codeine phosphate)	Diarrhoea

## Colchicine

Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

Indications

Gout

## Colecalciferol

Section

Vitamins and minerals

Oral > Liquid: 400 IU per mL

Oral > Solid: 400 IU; 1000 IU

Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Calcium deficiency

## Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistimethate sodium)

Indications

Other specified bacterial diseases

## Compound sodium lactate solution

Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: injectable solution

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypovolaemic shock

## Condoms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

## Copper-containing intrauterine device

Section

Intrauterine devices

-

Indications

Contact with health services for insertion of contraceptive device

## Crizotinib

Section	Indications
Targeted therapies	
Oral > Solid: 200 mg; 250 mg	Other specified malignant neoplasms of bronchus or lung
Oral > Solid > capsule: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive

## Cyanocobalamin

Section	Indications
Antianaemia medicines	Anaemias or other erythrocyte disorders

## Cyclizine

Section	Indications
Medicines for other common symptoms in palliative care	
Oral > Solid: 50 mg tablet	Palliative care
Parenteral > General injections > unspecified: 50 mg per mL	

## Cyclopentolate

Section	Indications
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide for Cycloplegic drug
Ophthalmological preparations > Mydriatics	Therapeutic equivalent to atropine for Anterior uveitis

## Cyclophosphamide

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Solid: 25 mg tablet	Burkitt lymphoma including Burkitt leukaemia
Parenteral > General injections > unspecified: 500 mg in vial powder for injection	Malignant neoplasms of breast
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection	Ewing sarcoma of bone and articular cartilage of unspecified sites
Oral > Solid: 25 mg; 50 mg	Lymphoid leukaemia, not elsewhere classified
Oral > Solid: 25 mg; 50 mg tablet	Chronic lymphocytic leukaemia or small lymphocytic lymphoma
	Diffuse large B-cell lymphomas
	Plasma cell myeloma
	Other specified gliomas of brain
	Other specified malignant neoplasms of breast
	Malignant trophoblastic neoplasms of placenta
	Follicular lymphoma
	Malignant neoplasms of kidney, except renal pelvis
	Rhabdomyosarcoma primary site
	Hodgkin lymphoma
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive

## Cycloserine

Section	Indications
Antituberculosis medicines	
Oral > Solid: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

## Cytarabine

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Lymphoid leukaemia, not elsewhere classified
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial	Myeloid leukaemia
	Acute myeloid leukaemia with recurrent genetic abnormalities
	Burkitt lymphoma including Burkitt leukaemia
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive
	Langerhans cell histiocytosis

## Dabigatran

Section	Indications
Medicines affecting coagulation	Venous thromboembolism
Oral > Solid: 110 mg; 150 mg	Other specified atrial fibrillation

## Dabrafenib

Section	Indications
Targeted therapies	Other specified melanoma of skin
Oral > Solid: 50 mg; 75 mg	

## Dacarbazine

Section	Indications
Cytotoxic medicines	Hodgkin lymphoma
Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	

## Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)	

## Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 60 mg + 400 mg	

## Dactinomycin

Section	Indications
Cytotoxic medicines	Malignant trophoblastic neoplasms of placenta
Parenteral > General injections > IV: 500 µg in vial powder for injection	Unspecified malignant neoplasms of ill-defined or unspecified sites
	Malignant neoplasms of kidney, except renal pelvis
	Rhabdomyosarcoma primary site
	Ewing sarcoma of bone and articular cartilage of unspecified sites

## Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for
	Acute ischaemic heart disease
	Therapeutic equivalent to enoxaparin for
	Venous thromboembolism

## Dapagliflozin

Section	Indications
Oral hypoglycaemic agents	Therapeutic equivalent to empagliflozin for
	Type 2 diabetes mellitus

## Dapsone

Section	Indications
Antileprosy medicines	Leprosy
Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	

## Daptomycin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

## Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

## Darbepoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

## Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	Chronic hepatitis C

## Dasatinib

Section	Indications
Targeted therapies Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myeloid leukaemia, not elsewhere classified

## Daunorubicin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)	Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities

## Deferoxamine

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

## Delafloxacin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 300 mg lyophilized powder for injection Oral > Solid: 450 mg	Methicillin resistant <i>Staphylococcus aureus</i>

## Delamanid

Section	Indications
Antituberculosis medicines Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

## Dengue vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

## Desmopressin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate) Local > Nasal > Spray: 10 µg per dose (acetate)	Haemophilia A Von Willebrand disease

## Dexamethasone

Section	Indications
<p>Other medicines administered to the mother</p> <p>Parenteral &gt; General injections &gt; unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))</p>	<p>Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy</p>
<p>Hormones and antihormones</p> <p>Oral &gt; Solid: 4 mg</p> <p>Parenteral &gt; General injections &gt; unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)</p> <p>Oral &gt; Liquid: 2 mg per 5 mL</p> <p>Oral &gt; Solid: 2 mg; 4 mg</p>	<p>Plasma cell myeloma</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>
<p>Antiallergics and medicines used in anaphylaxis</p> <p>Parenteral &gt; General injections &gt; unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)</p>	<p>Allergic or hypersensitivity conditions of unspecified type</p>
<p>Medicines for other common symptoms in palliative care</p> <p>Oral &gt; Liquid: 2 mg per 5 mL</p> <p>Oral &gt; Solid: 2 mg; 4 mg</p> <p>Parenteral &gt; General injections &gt; unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)</p>	<p>Palliative care</p>
<p>Antiemetic medicines</p> <p>Oral &gt; Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL</p> <p>Oral &gt; Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg</p> <p>Parenteral &gt; General injections &gt; unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)</p>	<p>Nausea or vomiting</p>

## Dextran 40

Section	Indications
Plasma substitutes	Hypovolaemia

## Dextran 70

Section	Indications
Plasma substitutes	Hypovolaemia

Parenteral > General injections > IV: 6% injectable solution

## Diaphragms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

## Diazepam

Section	Indications
Antiseizure medicines	Therapeutic equivalent to <a href="#">lorazepam</a> for
Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system	<a href="#">Status epilepticus</a>
Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube	<a href="#">Status epilepticus</a>
Medicines for other common symptoms in palliative care	Palliative care
Oral > Liquid: 2 mg per 5 mL	
Oral > Solid: 5 mg; 10 mg	
Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system	
Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube	
Parenteral > General injections > unspecified: 5 mg per mL	

## Diazoxide

Section	Indications
Medicines for hypoglycaemia	Persistent hyperinsulinaemic hypoglycaemia of infancy
Oral > Liquid: 50 mg per mL	
Oral > Solid: 50 mg	

## Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution  Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Diethylcarbamazine

Section	Indications
Antifilarials Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)	Lymphatic filariasis

## Digitoxin

Section	Indications
Medicines used in heart failure Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule Oral > Solid: 50 µg; 100 µg	Heart failure

## Digoxin

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule Oral > Liquid: 50 µg per mL Oral > Solid: 62.5 µg; 250 µg	Cardiac arrhythmia
Medicines used in heart failure Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule Oral > Liquid: 50 µg per mL Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg	Heart failure

## Dihydroartemisinin + piperaquine phosphate

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

## Dihydroergocryptine mesylate

Section	Indications
Antiseizure medicines Oral > Solid:	Parkinson disease

## Diloxanide

Section	Indications
Antiamoebic and antigiardiasis medicines Oral > Solid: 500 mg (furoate)	Amoebiasis

## Dimercaprol

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Diphtheria antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial	Need for immunization against diphtheria alone

## Diphtheria vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against diphtheria alone

## Diphtheria-pertussis-tetanus vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against diphtheria-tetanus-pertussis, combined

## Diphtheria-tetanus vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against combinations of infectious diseases

## Docetaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL	Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate Unspecified malignant neoplasms of ill-defined or unspecified sites

## Docusate sodium

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 50 mg per 5 mL oral liquid Oral > Solid: 100 mg capsule	Palliative care

## Dolasetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron for Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron for Nausea or vomiting

## Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Donepezil

Section	Indications
Medicines for diseases of the nervous system Oral > Liquid: 1 mg per mL (hydrochloride) Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)	Dementia due to Alzheimer disease

## Dopamine

Section	Indications
Medicines used in heart failure Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)	Heart failure Cardiogenic shock

## Doxorubicin

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)	Rhabdomyosarcoma primary site
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Follicular lymphoma
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)	Burkitt lymphoma including Burkitt leukaemia
	Ewing sarcoma of bone and articular cartilage of unspecified sites
	Malignant neoplasms of breast
	Lymphoid leukaemia, not elsewhere classified
	Other specified malignant neoplasms of breast
	Diffuse large B-cell lymphomas
	Plasma cell myeloma
	Malignant neoplasms of kidney, except renal pelvis
	Osteosarcoma of bone and articular cartilage of unspecified sites
	Kaposi sarcoma of unspecified primary site
	Hodgkin lymphoma
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive

## Doxycycline

Section	Indications
Access group antibiotics	First choice
Oral > Solid: 100 mg (as hyclate)	Chlamydia trachomatis
Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Second choice
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)	Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	Other indications
	Bacterial infection of unspecified site
Antimalarial medicines > For curative treatment	Malaria due to Plasmodium falciparum
Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)	Malaria due to Plasmodium falciparum
Antimalarial medicines > For chemoprevention	
Oral > Solid: 100 mg (hydrochloride or hyclate)	

## Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <a href="#">dabigatran</a> for <a href="#">Venous thromboembolism</a>
	Therapeutic equivalent to <a href="#">dabigatran</a> for <a href="#">Other specified atrial fibrillation</a>

## Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Solid: 600 mg tablet	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Efavirenz + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a> Therapeutic equivalent to <a href="#">efavirenz + emtricitabine + tenofovir</a> for <a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Eflornithine

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)	<a href="#">African trypanosomiasis</a>

## Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 50 mg + 100 mg	

## Empagliflozin

Section	Indications
Oral hypoglycaemic agents	Type 2 diabetes mellitus
Oral > Solid: 10 mg; 25 mg	

## Emtricitabine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors	
Oral > Liquid: 10 mg per mL	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Oral > Solid: 200 mg	

## Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals	
Oral > Solid: 200 mg + 25 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals	
Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	
Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
	Contact with or exposure to human immunodeficiency virus

## Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Enalapril

Section	Indications
Antihypertensive medicines Oral > Liquid: 1 mg per mL (as hydrogen maleate)	Essential hypertension
Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)	Heart failure

## Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to <a href="#">dabrafenib</a> for Other specified melanoma of skin

## Enoxaparin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule	Acute ischaemic heart disease Venous thromboembolism

## Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 0.05 mg per mL Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

## Enzalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate

## Ephedrine

Section	Indications
Local anaesthetics Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)	Cardiac complications of anaesthesia during labour or delivery

## Epinephrine

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)	Cardiac arrest
Ophthalmological preparations > Mydriatics Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)	Primary open-angle glaucoma
Antiasthmatic and medicines for chronic obstructive pulmonary disease Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)	Asthma Chronic obstructive pulmonary disease
Antiallergics and medicines used in anaphylaxis Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)	Anaphylaxis

## Epoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to <a href="#">erythropoiesis-stimulating agents</a> for <a href="#">Anaemia due to chronic disease</a>

## Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to <a href="#">erythropoiesis-stimulating agents</a> for <a href="#">Anaemia due to chronic disease</a>

## Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to <a href="#">erythropoiesis-stimulating agents</a> for <a href="#">Anaemia due to chronic disease</a>

## Equine rabies immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial	<a href="#">Rabies</a>

## Eravacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg lyophilized powder for injection	<a href="#">Carbapenem resistant Enterobacteriales</a>

## Ergocalciferol

Section	Indications
Vitamins and minerals	Therapeutic equivalent to <a href="#">colecalciferol</a> for
Oral > Liquid: 250 µg per mL (10 000 IU per mL)	<a href="#">Calcium deficiency</a>
Oral > Solid: 1.25 mg (50 000 IU)	Therapeutic equivalent to <a href="#">colecalciferol</a> for
	<a href="#">Vitamin D deficiency</a>
	<a href="#">Vitamin D deficiency</a>
	<a href="#">Calcium deficiency</a>

## Ergometrine

Section	Indications
Uterotonics	
Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	<a href="#">Postpartum haemorrhage</a>

## Erlotinib

Section	Indications
Targeted therapies	
Oral > Solid: 100 mg; 150 mg	<a href="#">Other specified malignant neoplasms of bronchus or lung</a>

## Erythromycin

Section	Indications
Watch group antibiotics	
Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)	<a href="#">Bacterial infection of unspecified site</a>
Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)	
Oral > Solid: 250 mg (as stearate or ethylsuccinate)	
Ophthalmological preparations > Anti-infective agents	<a href="#">Chlamydial conjunctivitis</a>
Local > Ophthalmological > Ointment: 0.5%	<a href="#">Gonococcal infection of eye</a>

## Erythropoiesis-stimulating agents

Section	Indications
<b>Antianaemia medicines</b> Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe	Anaemia due to chronic disease

## Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
<b>Injectable hormonal contraceptives</b> Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

## Etanercept

Section	Indications
<b>Immunomodulators for non-malignant disease</b>	Therapeutic equivalent to adalimumab for <b>Axial spondyloarthritis</b> Therapeutic equivalent to adalimumab for <b>Crohn disease site</b> Therapeutic equivalent to adalimumab for <b>Rheumatoid arthritis</b>
<b>Medicines for juvenile joint diseases</b>	Therapeutic equivalent to adalimumab for <b>Juvenile idiopathic arthritis</b>

## Ethambutol

Section	Indications
<b>Antituberculosis medicines</b> Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL  Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)	Other specified tuberculosis Tuberculosis

## Ethambutol + isoniazid

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg + 150 mg tablet	Tuberculosis

## Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet	Tuberculosis

## Ethambutol + isoniazid + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 275 mg + 75 mg + 150 mg tablet	Tuberculosis

## Ethanol

Section	Indications
Antiseptics Local > Topical > Solution: 70% (denatured)	Denatured alcohol

## Ether

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation > solution:	Anaesthetics and therapeutic gases

## Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 50 µg + 250 µg [4]	Contact with health services for postcoital contraception
Oral > Solid: 30 µg + 150 µg	Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

Section	Indications
Oral hormonal contraceptives Oral > Solid: 35 µg + 1 mg	Contact with health services for contraceptive management

## Ethionamide

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)	Multi-drug resistant <i>Mycobacterium tuberculosis</i> Tuberculous meningitis

## Ethosuximide

Section	Indications
Antiseizure medicines Oral > Liquid: 250 mg per 5 mL Oral > Solid: 250 mg	Absence seizures, typical

## Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

## Etoposide

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral &gt; General injections &gt; IV: 20 mg per mL in 5 mL ampoule</p> <p>Oral &gt; Solid: 100 mg capsule</p> <p>Parenteral &gt; General injections &gt; IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)</p> <p>Oral &gt; Solid: 100 mg capsule; 50 mg capsule</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Myeloid leukaemia</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Germ cell tumour of testis</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Hodgkin lymphoma</p> <p>Retinoblastoma</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>

## Everolimus

Section	Indications
<p>Targeted therapies</p> <p>Oral &gt; Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)</p>	Other specified gliomas of brain

## Fentanyl

Section	Indications
<p>Opioid analgesics</p> <p>Local &gt; Topical &gt; Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour</p> <p>Oral &gt; Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)</p> <p>Oral &gt; Other: 200 to 1200 µg buccal film (as citrate)</p>	<p>Chronic cancer pain</p> <p>Other specified chronic cancer related pain</p>

## Ferrous salt

Section	Indications
Antianaemia medicines	Iron deficiency anaemia
Oral > Liquid: 25 mg per mL iron (as sulfate)	
Oral > Solid: 60 mg iron	

## Ferrous salt + folic acid

Section	Indications
Antianaemia medicines	Iron deficiency anaemia
Oral > Solid: 60 mg iron + 2.8 mg	

## Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis	African trypanosomiasis
Oral > Solid: 600 mg	
Medicines for the treatment of 2nd stage African trypanosomiasis	African trypanosomiasis
Oral > Solid: 600 mg	

## Fexofenadine

Section	Indications
Antiallergics and medicines used in anaphylaxis	Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type

## Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

## Filgrastim

Section	Indications
Immunomodulators	Acquired neutropaenia
Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	

## Fingolimod

Section	Indications
Immunomodulators for non-malignant disease Oral > Solid: 0.25 mg; 0.5 mg	Relapsing-remitting multiple sclerosis

## Fluconazole

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 2 mg per mL in vial Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid Oral > Solid > capsule: 50 mg	Cryptococcosis Candidosis

## Flucytosine

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 2.5 g per 250 mL infusion Oral > Solid: 250 mg capsule	Cryptococcosis

## Fludarabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Fludrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes Oral > Solid: 100 µg (acetate)	Adrenocortical insufficiency

## Flunisolide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide for Asthma

## Fluorescein

Section	Indications
Diagnostic agents > Ophthalmic medicines Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)	Fluorescein

## Fluorouracil

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Ointment: 5%	Plantar warts
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > IV: 50 mg per mL in vial	Malignant neoplasms of nasopharynx
	Malignant neoplasm metastasis in large intestine
	Malignant neoplasms of breast
	Malignant neoplasms of rectum
	Malignant neoplasms of colon

## Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

## Fluticasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide for Asthma

## Fluticasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol for Asthma

## Fluticasone furoate + vilanterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to <a href="#">budesonide + formoterol</a> for <a href="#">Asthma</a>

## Fluvastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to <a href="#">simvastatin</a> for <a href="#">Mixed hyperlipidaemia</a>
	Therapeutic equivalent to <a href="#">simvastatin</a> for <a href="#">Coronary atherosclerosis</a>

## Folic acid

Section	Indications
Antianaemia medicines	<a href="#">Folate deficiency anaemia</a>
Oral > Solid: 1 mg tablet; 5 mg tablet	<a href="#">Anencephaly or similar anomalies</a>
Oral > Solid: 400 µg	<a href="#">Spina bifida</a>
	<a href="#">Cephalocele</a>

## Fomepizole

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Fosfomycin (injection)

Section	Indications
Reserve group antibiotics	<a href="#">Other specified bacterial diseases</a>
Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	<a href="#">Carbapenem resistant Acinetobacter baumannii</a>
	<a href="#">Carbapenem-resistant Pseudomonas aeruginosa</a>
	<a href="#">Carbapenem resistant Enterobacteriales</a>

## Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

## Fresh-frozen plasma

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Fulvestrant

Section	Indications
Hormones and antihormones Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

## Furosemide

Section	Indications
Medicines used in heart failure Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule  Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL  Oral > Solid > tablet: 40 mg; 20 mg	Heart failure
Diuretics Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule  Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL  Oral > Solid > tablet: 40 mg; 20 mg	Anuria or oliguria Oedema

## Gabapentin

Section	Indications
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg	Neuropathic pain

## Gallamine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)	Muscle relaxants

## Gatifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

## Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for  Other specified malignant neoplasms of bronchus or lung

## Gemcitabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary  Other specified malignant neoplasms of bronchus or lung

## Gentamicin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	<b>First choice</b>  Neonatal meningitis  co-prescribed with amoxicillin  Bacterial pneumonia (Community-acquired pneumonia - severe) [children]  co-prescribed with amoxicillin  Sepsis without septic shock  co-prescribed with ampicillin  Acute malnutrition in infants, children or adolescents (complicated) [children]  co-prescribed with ampicillin  Peritonitis (mild-moderate)  co-prescribed with ampicillin  Peritonitis (severe)  co-prescribed with ampicillin  Peritoneal abscess (severe)  co-prescribed with ampicillin  Sepsis without septic shock  co-prescribed with ampicillin  Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

	<p>co-prescribed with <b>ampicillin</b></p> <p><b>Peritoneal abscess (mild-moderate)</b></p>
	<p>co-prescribed with <b>benzylpenicillin</b></p> <p><b>Acute malnutrition in infants, children or adolescents (complicated) [children]</b></p>
	<p>co-prescribed with <b>benzylpenicillin</b></p> <p><b>Sepsis without septic shock</b></p>
	<p>co-prescribed with <b>benzylpenicillin</b></p> <p><b>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</b></p>
	<p><b>Second choice</b></p> <p><b>Other specified prophylactic measures</b></p> <p><b>Gonococcal infection</b></p>
	<p><b>Other indications</b></p> <p><b>Bacterial infection of unspecified site</b></p>
	<p><b>Other specified conjunctivitis</b></p> <p><b>Infectious blepharitis</b></p>

## Glass ionomer cement

Section	Indications
Dental medicines and preparations Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid	<b>Dental caries</b>

## Glatiramer acetate

Section	Indications
Medicines for multiple sclerosis Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe	<b>Relapsing-remitting multiple sclerosis</b> <b>Multiple sclerosis</b>

## Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules	<b>Chronic hepatitis C</b>

## Glibenclamide

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 5 mg; 2.5 mg	Type 2 diabetes mellitus

## Gliclazide

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release	Type 2 diabetes mellitus

## Glucagon

Section	Indications
Medicines for hypoglycaemia Parenteral > General injections > unspecified: 1 mg per mL	Hypoglycaemia in the context of diabetes

## Glucose

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral	Other specified disorders of fluid, electrolyte or acid-base balance
Parenteral > General injections > IV: 5% isotonic; 10% hypertonic	Hypoglycaemia without associated diabetes
Parenteral > General injections > IV: 50% hypertonic	

## Glucose + sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral  Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

## Glutaral

Section	Indications
Disinfectants Local > Topical > Solution: 2%	Glutaral nonmedicinal

## Glyceryl trinitrate

Section	Indications
Antianginal medicines Oral > Solid: 500 µg sublingual tablet	Angina pectoris

## Glycopyrronium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to <a href="#">tiotropium bromide</a> for <a href="#">Chronic obstructive pulmonary disease</a>

## Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to <a href="#">adalimumab</a> for <a href="#">Axial spondyloarthritis</a>
	Therapeutic equivalent to <a href="#">adalimumab</a> for <a href="#">Crohn disease site</a>
	Therapeutic equivalent to <a href="#">adalimumab</a> for <a href="#">Rheumatoid arthritis</a>
Medicines for juvenile joint diseases	Therapeutic equivalent to <a href="#">adalimumab</a> for <a href="#">Juvenile idiopathic arthritis</a>

## Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to <a href="#">leuprorelin</a> for <a href="#">Malignant neoplasms of breast</a>
	Therapeutic equivalent to <a href="#">leuprorelin</a> for <a href="#">Malignant neoplasms of prostate</a>

## Granisetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to <a href="#">ondansetron</a> for <a href="#">Palliative care</a>
Antiemetic medicines	Therapeutic equivalent to <a href="#">ondansetron</a> for <a href="#">Nausea or vomiting</a>

## Griseofulvin

Section	Indications
Antifungal medicines Oral > Liquid: 125 mg per 5 mL Oral > Solid: 125 mg; 250 mg	<a href="#">Dermatophytosis</a>

## Haemophilus influenzae type b vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

## Haloperidol

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 2 mg per mL Oral > Solid: 0.5 mg; 2 mg; 5 mg Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule	<a href="#">Palliative care</a>

## Halothane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation > liquid:	<a href="#">Anaesthetics and therapeutic gases</a>

## Heparin sodium

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule	Acute ischaemic heart disease Unstable angina Venous thromboembolism

## Hepatitis a vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

## Hepatitis b vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against viral hepatitis

## Homatropine

Section	Indications
Ophthalmological preparations > Mydriatics Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)	Anterior uveitis Therapeutic equivalent to atropine for Anterior uveitis

## Human papilloma virus (HPV) vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

## Hydralazine

Section	Indications
Antihypertensive medicines Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)  Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)  Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)	Essential hypertension Gestational hypertension

## Hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Liquid: 50 mg per 5 mL Oral > Solid: 25 mg; 12.5 mg	Essential hypertension
Medicines used in heart failure Oral > Liquid: 50 mg per 5 mL Oral > Solid: 25 mg	Heart failure
Diuretics Oral > Solid: 25 mg	Oedema

## Hydrocortisone

Section	Indications
Hormones and antihormones Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia
Adrenal hormones and synthetic substitutes Oral > Solid: 5 mg; 10 mg; 20 mg	Adrenocortical insufficiency
Ophthalmological preparations > Anti-inflammatory agents Local > Ophthalmological > Ointment: 1% (acetate)	Scleritis Anterior uveitis
Antiallergics and medicines used in anaphylaxis Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)	Anaphylaxis
Anti-inflammatory medicines Local > Rectal > Suppository: 25 mg (acetate) Local > Rectal > Retention enema: 100 mg per 60 mL	Crohn disease site Ulcerative colitis
Dermatological medicines > Anti-inflammatory and antipruritic medicines Local > Topical > Cream: 1% (acetate) Local > Topical > Ointment: 1% (acetate)	Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type

## Hydromorphone

Section	Indications
Opioid analgesics	Therapeutic equivalent to <a href="#">morphine</a> for <a href="#">Pain</a>

## Hydroxocobalamin

Section	Indications
Antianaemia medicines Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)	<a href="#">Megaloblastic anaemia due to vitamin B12 deficiency</a>

## Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	<a href="#">Squamous cell carcinoma of oropharynx</a> <a href="#">Chronic myeloid leukaemia, not elsewhere classified</a>
Other medicines for haemoglobinopathies Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg	<a href="#">Other specified sickle cell disorders or other haemoglobinopathies</a>

## Hydroxychloroquine

Section	Indications
Antimalarial medicines > For chemoprevention	Therapeutic equivalent to <a href="#">chloroquine</a> for <a href="#">Malaria due to Plasmodium falciparum</a>
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 200 mg (as sulfate)	<a href="#">Systemic lupus erythematosus</a> <a href="#">Cutaneous lupus erythematosus of unspecified type</a>

## Hyoscine butylbromide

Section	Indications
Medicines for other common symptoms in palliative care Parenteral > General injections > unspecified: 20 mg per mL injection	<a href="#">Palliative care</a>

## Hyoscine hydrobromide

Section	Indications
Medicines for other common symptoms in palliative care Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch  Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection	Palliative care

## Hypochlorous acid

Section	Indications
Antiseptics Local > Topical > Solution:	Disinfectant, not elsewhere classified

## Ibrutinib

Section	Indications
Targeted therapies Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ibuprofen

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 5 mg per mL	Patent arterial duct
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL  Oral > Solid > tablet: 200 mg; 400 mg; 600 mg	Pain
Antimigraine medicines > For treatment of acute attack Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL  Oral > Solid > tablet: 200 mg; 400 mg	Migraine

## Idoxuridine

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Solution (eye drops): 0.1%  Local > Ophthalmological > Ointment: 0.2%	Herpes simplex keratitis

## Ifosfamide

Section	Indications
Cytotoxic medicines	Other specified malignant neoplasms of the ovary
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection	Germ cell tumour of testis
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Ewing sarcoma of bone and articular cartilage of unspecified sites
	Osteosarcoma of bone and articular cartilage of unspecified sites
	Rhabdomyosarcoma primary site
	Unspecified malignant neoplasms of ill-defined or unspecified sites
	Burkitt lymphoma including Burkitt leukaemia
	Malignant neoplasms of kidney, except renal pelvis
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive

## Imatinib

Section	Indications
Targeted therapies	B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1
Oral > Solid: 100 mg; 400 mg	Gastrointestinal stromal tumour of unspecified gastrointestinal sites
	Chronic myeloid leukaemia, not elsewhere classified

## Imipenem + cilastatin

Section	Indications
Watch group antibiotics  Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	<p>Second choice</p> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <ul style="list-style-type: none"><li><a href="#">Neutropenia (high-risk)</a></li><li>Therapeutic equivalent to <a href="#">meropenem</a> for</li><li><a href="#">Peritoneal abscess (severe)</a></li><li>Therapeutic equivalent to <a href="#">meropenem</a> for</li><li><a href="#">Peritonitis (severe)</a></li></ul>
Antituberculosis medicines	<p>Other indications</p> <ul style="list-style-type: none"><li><a href="#">Pseudomonas aeruginosa resistant to other antibiotic</a></li><li><a href="#">Antibiotic resistant Acinetobacter baumannii</a></li></ul> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <ul style="list-style-type: none"><li><a href="#">Multi-drug resistant Mycobacterium tuberculosis</a></li></ul>

## Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics  Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	<ul style="list-style-type: none"><li><a href="#">Other specified other antibiotic resistant Enterobacteriales</a></li><li><a href="#">Carbapenem resistant Enterobacteriales</a></li><li><a href="#">Carbapenem-resistant Pseudomonas aeruginosa</a></li></ul>

## Indapamide

Section	Indications
Antihypertensive medicines	<p>Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for</p> <ul style="list-style-type: none"><li><a href="#">Essential hypertension</a></li></ul>
Medicines used in heart failure	<p>Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for</p> <ul style="list-style-type: none"><li><a href="#">Heart failure</a></li></ul>

## Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Indometacin

Section	Indications
Medicines administered to the neonate [c]	Therapeutic equivalent to ibuprofen for Patent arterial duct

## Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis
	Therapeutic equivalent to adalimumab for Crohn disease site
	Therapeutic equivalent to adalimumab for Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis

## Influenza vaccine (seasonal)

Section	Indications
Recommendations for immunization programmes with certain characteristics  All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against influenza

## Insulin analogues

Section	Indications
Insulins  Not specified	Type 1 diabetes mellitus  Type 2 diabetes mellitus

## Insulin degludec

Section	Indications
<b>Insulins</b> Parenteral > General injections > SC: 100 units per mL	Therapeutic equivalent to <a href="#">insulin glargine</a> for <b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 2 diabetes mellitus</b>

## Insulin detemir

Section	Indications
<b>Insulins</b>	Therapeutic equivalent to <a href="#">insulin glargine</a> for <b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 2 diabetes mellitus</b>

## Insulin glargine

Section	Indications
<b>Insulins</b> Parenteral > General injections > SC: 100 units per mL	<b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 1 diabetes mellitus</b> Therapeutic equivalent to <a href="#">long-acting insulin analogues</a> for <b>Type 2 diabetes mellitus</b>

## Intraperitoneal dialysis solution

Section	Indications
<b>Peritoneal dialysis solution</b> parenteral solution	<b>Care involving peritoneal dialysis</b>

## Iodine

Section	Indications
Vitamins and minerals	Iodine deficiency
Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle Oral > Solid: 190 mg	
Antiseptics	Therapeutic equivalent to povidone iodine for Povidone iodine

## Iohexol

Section	Indications
Diagnostic agents > Radiocontrast media Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule	X-ray contrast media, iodinated

## Ipecacuanha

Section	Indications
Antidotes and other substances used in poisonings > Non-specific Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine	Unspecified injury, poisoning or certain other consequences of external causes

## Ipratropium bromide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Respiratory > Inhalation > aerosol: 20 µg per dose	Asthma Chronic obstructive pulmonary disease

## Irinotecan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site

## Isoflurane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines	Anaesthetics and therapeutic gases
Respiratory > Inhalation > liquid:	

## Isoniazid

Section	Indications
Antituberculosis medicines	Other specified tuberculosis
Parenteral > General injections > IV: 100 mg per mL	Tuberculosis
Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet	

## Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)	

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections	Other specified prophylactic measures
Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	

## Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet	

## Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines	Latent tuberculosis
Oral > Solid: 300 mg + 300 mg tablet (scored)	

## Isoprenaline

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)  Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)	Bradycardia  Cardiogenic shock

## Isosorbide dinitrate

Section	Indications
Antianginal medicines Oral > Solid: 5 mg sublingual tablet	Angina pectoris

## Itraconazole

Section	Indications
Antifungal medicines Oral > Liquid: 10 mg per mL  Oral > Solid: 100 mg	Chronic pulmonary aspergillosis  Chromoblastomycosis  Histoplasmosis  Talaromycosis  Sporotrichosis  Paracoccidioidomycosis

## Ivermectin

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 3 mg	Strongyloidiasis  Ascariasis  Trichuriasis  Hookworm diseases  Ancylostomiasis
Antifilarials Oral > Solid > tablet: 3 mg	Onchocerciasis  Lymphatic filariasis
Medicines for ectoparasitic infections Oral > Solid > tablet: 3 mg	Scabies

## Kanamycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to <a href="#">gentamicin</a> for <a href="#">Other specified conjunctivitis</a>
	Therapeutic equivalent to <a href="#">gentamicin</a> for <a href="#">Infectious blepharitis</a>

## Kanamycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	<a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>

## Ketamine

Section	Indications
General anaesthetics and oxygen > Injectable medicines Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)	<a href="#">Anaesthetics and therapeutic gases</a>

## Lactulose

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid	<a href="#">Palliative care</a>

## Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid: 150 mg tablet	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	<p>Therapeutic equivalent to emtricitabine + tenofovir for</p> <p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p> <p>Therapeutic equivalent to emtricitabine + tenofovir for</p> <p>Contact with or exposure to human immunodeficiency virus</p>

## Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamotrigine

Section	Indications
Antiseizure medicines Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)	Epilepsy or seizures

## Latanoprost

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops	Primary open-angle glaucoma

## Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

## Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

## Leuprorelin

Section	Indications
Hormones and antihormones Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

## Levamisole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)	Ascariasis

## Levetiracetam

Section	Indications
Antiseizure medicines	Epilepsy or seizures
Oral > Liquid: 100 mg per mL	
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg	
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag	Status epilepticus

## Levodopa

Section	Indications
Antiseizure medicines	Parkinson disease
Oral > Solid: 250 mg	

## Levodopa + benserazide

Section	Indications
Medicines for parkinsonism	Therapeutic equivalent to levodopa + carbidopa for Parkinson disease

## Levodopa + carbidopa

Section	Indications
Medicines for parkinsonism	
Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet	Parkinson disease

## Levofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)	Multi-drug resistant Mycobacterium tuberculosis

## Levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 750 µg [2]; 1.5 mg [1]	Contact with health services for postcoital contraception
Oral > Solid: 30 µg	Contact with health services for contraceptive management
Intrauterine devices Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

## Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

## Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

## Lidocaine

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)	Ventricular tachyarrhythmia
Local anaesthetics Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride) Local > Topical > unspecified: 2 to 4% (hydrochloride)	Local anaesthetics

## Lidocaine + epinephrine

Section	Indications
<p>Local anaesthetics</p> <p>Parenteral &gt; Locoregional injections &gt; Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial</p> <p>Local &gt; Dental &gt; Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine</p>	Local anaesthetics

## Lindane

Section	Indications
<p>Dermatological medicines &gt; Scabicides and pediculicides</p> <p>Local &gt; Topical &gt; Cream: 1%</p> <p>Local &gt; Topical &gt; Lotion: 1%</p>	Scabies

## Linezolid

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 2 mg per mL in 300 mL bag</p> <p>Oral &gt; Liquid: 100 mg per 5 mL powder for oral liquid</p> <p>Oral &gt; Solid: 400 mg tablet; 600 mg tablet</p>	Other specified bacterial diseases
<p>Antituberculosis medicines</p> <p>Oral &gt; Solid: 600 mg tablet; 150 mg tablet (dispersible)</p>	Multi-drug resistant Mycobacterium tuberculosis

## Lisinopril + amlodipine

Section	Indications
<p>Antihypertensive medicines</p> <p>Oral &gt; Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg</p>	Essential hypertension

## Lisinopril + hydrochlorothiazide

Section	Indications
<p>Antihypertensive medicines</p> <p>Oral &gt; Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg</p>	Essential hypertension

## Lisocabtagene maraleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to <a href="#">axicabtagene ciloleucel</a> for <b>Diffuse large B-cell lymphomas</b>

## Lithium carbonate

Section	Indications
Medicines for bipolar disorders Oral > Solid: 300 mg	<b>Bipolar or related disorders</b>

## Long-acting insulin analogues

Section	Indications
Insulins Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	<b>Type 1 diabetes mellitus</b> <b>Type 2 diabetes mellitus</b>

## Loperamide

Section	Indications
Medicines for other common symptoms in palliative care Oral > Solid: 2 mg solid oral dosage form	<b>Palliative care</b>

## Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg	<b>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</b>

## Loratadine

Section	Indications
Antiallergics and medicines used in anaphylaxis Oral > Liquid: 1 mg per mL Oral > Solid: 10 mg	<b>Allergic or hypersensitivity conditions of unspecified type</b>

## Lorazepam

Section	Indications
Antiseizure medicines Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule	Status epilepticus

## Losartan

Section	Indications
Antihypertensive medicines Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Essential hypertension
Medicines used in heart failure Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Heart failure

## Lovastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia
	Therapeutic equivalent to simvastatin for Coronary atherosclerosis

## Lugol's solution

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)	Thyrotoxicosis

## Magnesium sulfate

Section	Indications
Antiseizure medicines Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)  Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)	Severe pre-eclampsia Eclampsia

## Mannitol

Section	Indications
Diuretics Parenteral > General injections > IV: 10% solution; 20% solution	Ocular hypertension Cerebral oedema

## Measles vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against measles alone

## Mebendazole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Ascariasis Enterobiasis Trichuriasis Hookworm diseases
Cysticidal medicines Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)	Other specified echinococcosis

## Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 150 mg per mL in 1 mL vial Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

## Mefloquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > For chemoprevention Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

## Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

## Meglumine iotroxate

Section	Indications
Diagnostic agents > Radiocontrast media Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL	X-ray contrast media, iodinated

## Melarsoprol

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)	African trypanosomiasis

## Melphalan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg	Plasma cell myeloma

## Meningococcal meningitis vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

## Mercaptopurine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis

## Meropenem

Section	Indications
<b>Watch group antibiotics</b> Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choice <b>Neutropenia (high-risk)</b> <b>Peritoneal abscess (severe)</b> <b>Peritonitis (severe)</b> <b>Neonatal meningitis</b>
<b>Antituberculosis medicines</b> Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	<b>Multi-drug resistant Mycobacterium tuberculosis</b>

## Meropenem + vaborbactam

Section	Indications
<b>Reserve group antibiotics</b> Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	<b>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></b> <b>Carbapenem resistant <i>Enterobacteriales</i></b> <b>Carbapenem resistant <i>Acinetobacter baumannii</i></b>

## Mesalazine

Section	Indications
<b>Anti-inflammatory medicines</b>	Therapeutic equivalent to <b>sulfasalazine</b> for <b>Crohn disease site</b> Therapeutic equivalent to <b>sulfasalazine</b> for <b>Ulcerative colitis</b>

## Mesna

Section	Indications
<p><b>Supportive medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule</p> <p>Oral &gt; Solid: 400 mg; 600 mg</p>	<p>Osteosarcoma of bone and articular cartilage of other specified sites</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p>

## Metformin

Section	Indications
<p><b>Oral hypoglycaemic agents</b></p> <p>Oral &gt; Solid: 500 mg (hydrochloride)</p>	Type 2 diabetes mellitus

## Methadone

Section	Indications
<p><b>Medicines for opioid use disorders</b></p> <p>Oral &gt; Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)</p>	Opioid dependence
<p><b>Opioid analgesics</b></p> <p>Oral &gt; Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)</p>	Chronic cancer pain
<p>Oral &gt; Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)</p>	

## Methimazole

Section	Indications
<p><b>Thyroid hormones and antithyroid medicines</b></p> <p>Oral &gt; Solid: 5 mg; 10 mg; 20 mg</p>	Thyrotoxicosis

## Methionine

Section	Indications
Antidotes and other substances used in poisonings > Specific Oral > Solid: 250 mg (DL)	Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

## Methotrexate

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as sodium salt) Oral > Solid: 2.5 mg (as sodium salt) Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
Dermatological medicines > Medicines affecting skin differentiation and proliferation Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)	Psoriasis of unspecified type
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid > tablet: 2.5 mg (as sodium salt)	Rheumatoid arthritis, serology unspecified
Immunomodulators for non-malignant disease Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis
Medicines for juvenile joint diseases Oral > Solid > tablet: 2.5 mg (as sodium salt)	Juvenile idiopathic arthritis

## Methoxy polyethylene glycol-epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

## Methyldopa

Section	Indications
Antihypertensive medicines Oral > Solid: 250 mg	Essential hypertension Gestational hypertension

## Methylergometrine

Section	Indications
Uterotonics	Therapeutic equivalent to ergometrine for Postpartum haemorrhage

## Methylphenidate

Section	Indications
Medicines for mental and behavioural disorders Multiple formulations and strengths.	Attention deficit hyperactivity disorder

## Methylprednisolone

Section	Indications
Hormones and antihormones Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia

## Methylthioninium chloride

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule	Acquired methaemoglobinuria

## Metoclopramide

Section	Indications
Medicines for other common symptoms in palliative care	Palliative care
Oral > Liquid: 5 mg per 5 mL	
Oral > Solid: 10 mg (hydrochloride)	
Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	
Antiemetic medicines	Nausea or vomiting
Oral > Liquid: 5 mg per 5 mL	
Oral > Solid: 10 mg (hydrochloride)	
Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	

## Metoprolol

Section	Indications
Antianginal medicines	Therapeutic equivalent to <b>bisoprolol</b> for Angina pectoris
Medicines used in heart failure	Therapeutic equivalent to <b>bisoprolol</b> for Heart failure
Antihypertensive medicines	Therapeutic equivalent to <b>bisoprolol</b> for Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to <b>bisoprolol</b> for Cardiac arrhythmia

## Metronidazole

Section	Indications
<b>Access group antibiotics</b> Oral > Liquid: 200 mg per 5 mL (as benzoate) Oral > Solid: 200 to 500 mg tablet Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection Local > Rectal > Suppository: 500 mg suppository; 1 g suppository	<b>First choice</b> co-prescribed with <b>cefazolin</b> <b>Other specified prophylactic measures</b> co-prescribed with <b>cefotaxime</b> <b>Peritoneal abscess (severe)</b> co-prescribed with <b>cefotaxime</b> <b>Peritonitis (mild-moderate)</b> co-prescribed with <b>cefotaxime</b> <b>Peritoneal abscess (mild-moderate)</b> co-prescribed with <b>cefotaxime</b> <b>Peritonitis (severe)</b> co-prescribed with <b>ceftriaxone</b> <b>Peritoneal abscess (severe)</b> co-prescribed with <b>ceftriaxone</b> <b>Peritoneal abscess (mild-moderate)</b> co-prescribed with <b>ceftriaxone</b> <b>Peritonitis (mild-moderate)</b> co-prescribed with <b>ceftriaxone</b> <b>Peritonitis (severe)</b> <b>Second choice</b> co-prescribed with <b>ciprofloxacin</b> <b>Peritoneal abscess (mild-moderate)</b> co-prescribed with <b>ciprofloxacin</b> <b>Peritonitis (mild-moderate)</b> <b>Other indications</b> <b>Bacterial infection of unspecified site</b> <b>Amoebiasis</b>
<b>Antiamoebic and antigiardiasis medicines</b> Oral > Liquid: 200 mg per 5 mL (as benzoate) Parenteral > General injections > unspecified: 500 mg in 100 mL vial Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	

## Micafungin

Section	Indications
<b>Antifungal medicines</b> Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection	<b>Systemic or invasive candidosis</b>

## Miconazole

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Cream: 2% (nitrate) Local > Topical > Ointment: 2% (nitrate)	Fungal infection of the skin

## Midazolam

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 2 mg per mL oral liquid Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection	Palliative care
Antiseizure medicines Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration) Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)	Therapeutic equivalent to lorazepam for Status epilepticus Status epilepticus
Preoperative medication and sedation for short-term procedures Parenteral > General injections > IV: 1 mg per mL Oral > Liquid: 2 mg per mL Oral > Solid: 15 mg tablet; 7.5 mg tablet	Sedative-hypnotic and anxiolytic drugs

## Mifepristone - misoprostol

Section	Indications
Uterotonics Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	Induced abortion

## Miltefosine

Section	Indications
Antileishmaniasis medicines	Visceral leishmaniasis
Oral > Solid: 10 mg; 50 mg	Mucocutaneous leishmaniasis
	Cutaneous leishmaniasis

## Misoprostol

Section	Indications
Uterotonics	Spontaneous abortion, incomplete, without complication
Oral > Solid: 200 µg	Unspecified obstetric condition
Local > Vaginal > tablet: 25 µg	Postpartum haemorrhage

## Mometasone

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide for Asthma

## Mometasone + formoterol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to budesonide + formoterol for Asthma

## Morphine

Section	Indications
<p>Preoperative medication and sedation for short-term procedures Parenteral &gt; General injections &gt; IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)</p> <p>Opioid analgesics Oral &gt; Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate) Oral &gt; Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate) Oral &gt; Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate) Parenteral &gt; General injections &gt; unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)</p>	<p>Opioids or related analgesics and agents affecting opioid receptors</p> <p>Pain</p>

## Moxifloxacin

Section	Indications
<p>Antituberculosis medicines Oral &gt; Solid: 400 mg tablet; 100 mg tablet (dispersible) Oral &gt; Solid: 400 mg tablet</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Tuberculosis</p>

## Multiple micronutrient powder

Section	Indications
<p>Vitamins and minerals Oral &gt; Other:</p>	<p>Iron deficiency anaemia</p>

## Multiple micronutrient supplement

Section	Indications
<p>Other medicines administered to the mother Tablet containing:</p> <p>Vit A: 800 mcg retinol activity equivalent</p> <p>Vit C: 70 mg</p> <p>Vit D: 5 mcg (200 IU)</p> <p>Vit E: 10 mg alpha tocopherol equivalent</p> <p>Vit B1: 1.4 mg</p> <p>Vit B2: 1.4 mg</p> <p>Vit B3: 18 mg niacin equivalent</p> <p>Vit B6: 1.9 mg</p> <p>Folic acid: 400 mcg</p> <p>Vit B12: 2.6 mcg</p> <p>Iron: 30 mg</p> <p>Iodine: 150 mcg</p> <p>Zinc: 15 mg</p> <p>Selenium: 65 mcg</p> <p>Copper: 2 mg</p>	<p>Maternal care for other specified conditions predominantly related to pregnancy</p>

## Mumps vaccine

Section	Indications
<p>Recommendations for immunization programmes with certain characteristics</p> <p>All vaccines should comply with the WHO requirements for biological substances.</p>	<p>Need for immunization against mumps alone</p>

## Mupirocin

Section	Indications
<p>Dermatological medicines &gt; Anti-infective medicines Local &gt; Topical &gt; Cream: 2% (as mupirocin calcium) Local &gt; Topical &gt; Ointment: 2%</p>	<p>Superficial bacterial folliculitis</p> <p>Impetigo</p>

## Nadroparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <a href="#">enoxaparin</a> for <b>Acute ischaemic heart disease</b>
	Therapeutic equivalent to <a href="#">enoxaparin</a> for <b>Venous thromboembolism</b>

## Nalidixic acid

Section	Indications
Anti-infective medicines Oral > Solid: 250 mg; 500 mg	<b>Shigella</b> resistant to unspecified antibiotic

## Naloxone

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)	<b>Unintentional exposure to or harmful effects of opioids or related analgesics</b>

## Natamycin

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Suspension: 5% eye drops	<b>Infectious keratitis</b>

## Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 250 mg (as mesilate) Oral > Other: 50 mg per g oral powder	<b>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</b>

## Neostigmine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Oral > Solid: 15 mg (neostigmine bromide) Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)	<b>Myasthenia gravis</b> <b>Anticholinesterase reversible</b>

## Netilmicin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to <a href="#">gentamicin</a> for <a href="#">Other specified conjunctivitis</a>
	Therapeutic equivalent to <a href="#">gentamicin</a> for <a href="#">Infectious blepharitis</a>

## Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL oral solution Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)	<a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a>

## Niclosamide

Section	Indications
Intestinal anthelmintics Oral > Solid: 500 mg tablet (chewable)	<a href="#">Hymenolepasis</a> <a href="#">Diphyllobothriasis</a> <a href="#">Taeniasis due to Taenia saginata</a> <a href="#">Taeniasis due to Taenia solium</a>

## Nicotinamide

Section	Indications
Vitamins and minerals Oral > Solid: 50 mg	<a href="#">Pellagra</a>

## Nifedipine

Section	Indications
Antioxytocics (tocolytics) Oral > Solid: 10 mg (immediate-release)	<a href="#">Preterm labour without delivery</a>
Antianginal medicines Oral > Solid: 10 mg	<a href="#">Angina pectoris</a>
Antihypertensive medicines Oral > Solid: 10 mg tablet; sustained-release formulations	<a href="#">Essential hypertension</a>

## Nifurtimox

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)	African trypanosomiasis
American trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Chagas disease

## Nilotinib

Section	Indications
Targeted therapies Oral > Solid: 150 mg capsule; 200 mg capsule	Chronic myeloid leukaemia, not elsewhere classified

## Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

## Nitrous oxide

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation:	Anaesthetics and therapeutic gases

## Nivolumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Melanoma of skin

## Norethisterone

Section	Indications
Oral hormonal contraceptives Oral > Solid: 350 µg	Contact with health services for contraceptive management
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle

## Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

## Normal immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 5% protein solution; 10% protein solution Parenteral > General injections > IM: 16% protein solution Parenteral > General injections > SC: 15% protein solution; 16% protein solution	Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis

## Nystatin

Section	Indications
Antifungal medicines Oral > Liquid: 100000 IU per mL Local > Topical > Other: 100000 IU pessary Oral > Solid > dosage form: 500000 IU Oral > Solid > lozenge: 100000 IU	Candidosis

## Ocrelizumab

Section	Indications
Medicines for multiple sclerosis Parenteral > General injections > IV: 30 mg per mL in 10 mL vial Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution	Relapsing-remitting multiple sclerosis Multiple sclerosis

## Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Ear, nose and throat medicines [c]	Therapeutic equivalent to <i>ciprofloxacin</i> for Infectious diseases of external ear
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Solution (eye drops): 0.3%	Other specified conjunctivitis Infectious keratitis

## Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant <i>Staphylococcus aureus</i>

## Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

## Omeprazole

Section	Indications
Antiulcer medicines Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid Oral > Solid: 10 mg; 20 mg; 40 mg Parenteral > General injections > IV: 40 mg in vial	Peptic ulcer, site unspecified Gastro-oesophageal reflux disease Gastrointestinal bleeding

## Ondansetron

Section	Indications
<p><b>Medicines for other common symptoms in palliative care</b></p> <p>Parenteral &gt; General injections &gt; IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)</p> <p>Oral &gt; Liquid: 4 mg per 5 mL (ondansetron base)</p> <p>Oral &gt; Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)</p>	Palliative care
<p><b>Antiemetic medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)</p> <p>Oral &gt; Liquid: 4 mg per 5 mL (ondansetron base)</p> <p>Oral &gt; Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)</p>	Nausea or vomiting

## Oral rehydration salts

Section	Indications
<p><b>Oral rehydration</b></p> <p>Powder for dilution in 200 mL, 500 mL, 1 L:</p> <ul style="list-style-type: none"><li>- glucose 75 mEq</li><li>- sodium 75 mEq or mmol/L</li><li>- chloride 65 mEq or mmol/L</li><li>- potassium 20 mEq or mmol/L</li><li>- citrate 10 mmol/L</li><li>- osmolarity 245 mOsm/L</li><li>- glucose 13.5 g/L</li><li>- sodium chloride 2.6 g/L</li><li>- potassium chloride 1.5 g/L</li><li>- trisodium citrate dihydrate 2.9 g/L</li></ul>	Diarrhoea
<p><b>Solutions correcting water, electrolyte and acid-base disturbances &gt; Oral</b></p> <p>Powder for dilution in 200 mL, 500 mL, 1 L:</p> <ul style="list-style-type: none"><li>- glucose 75 mEq</li><li>- sodium 75 mEq or mmol/L</li><li>- chloride 65 mEq or mmol/L</li><li>- potassium 20 mEq or mmol/L</li><li>- citrate 10 mmol/L</li><li>- osmolarity 245 mOsm/L</li><li>- glucose 13.5 g/L</li><li>- sodium chloride 2.6 g/L</li><li>- potassium chloride 1.5 g/L</li><li>- trisodium citrate dihydrate 2.9 g/L</li></ul>	Other specified disorders of fluid, electrolyte or acid-base balance

## Oral rehydration salts - zinc sulfate

Section	Indications
<p><b>Medicines used in diarrhoea</b></p> <p>Oral &gt; Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)</p>	Diarrhoea

## Oseltamivir

Section	Indications
<p><b>Other antivirals</b></p> <p>Oral &gt; Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)</p>	Influenza due to identified seasonal influenza virus

## Oxaliplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

## Oxamniquine

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Liquid: 250 mg per 5 mL Oral > Solid: 250 mg capsule	Schistosomiasis due to <i>Schistosoma mansoni</i>

## Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

## Oxycodone

Section	Indications
Opioid analgesics	Therapeutic equivalent to <a href="#">morphine</a> for Pain

## Oxygen

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation: (medical gas)	Anaesthetics and therapeutic gases
Medical gases Respiratory > Inhalation:	Respiratory failure as acute or chronic

## Oxytetracycline

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Other specified conjunctivitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Infectious keratitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Infectious blepharitis</a>
	Therapeutic equivalent to <a href="#">tetracycline</a> for <a href="#">Trachoma</a>

## Oxytocin

Section	Indications
Uterotonics Parenteral > General injections > unspecified: 10 IU per mL	<a href="#">Postpartum haemorrhage</a>

## P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)	<a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>

## P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	<a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>

## Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

## Palonosetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to <a href="#">ondansetron</a> for <a href="#">Palliative care</a>
Antiemetic medicines	Therapeutic equivalent to <a href="#">ondansetron</a> for <a href="#">Nausea or vomiting</a>

## Pancreatic enzymes

Section	Indications
Pancreatic enzymes Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.	<a href="#">Enzyme intestinal</a>

## Paracetamol (acetaminophen)

Section	Indications
<p>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)</p> <p>Oral &gt; Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL</p> <p>Local &gt; Rectal &gt; Suppository: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; dispersible tablet: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; tablet: 250 mg; 325 mg; 500 mg</p> <p>Antimigraine medicines &gt; For treatment of acute attack</p> <p>Oral &gt; Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL</p> <p>Local &gt; Rectal &gt; Suppository: 250 mg</p> <p>Oral &gt; Solid &gt; dispersible tablet: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; tablet: 250 mg; 325 mg; 500 mg</p>	Pain
	Migraine

## Paromomycin

Section	Indications
<p>Antileishmaniasis medicines</p> <p>Parenteral &gt; General injections &gt; IM: 750 mg paromomycin base (as sulfate)</p>	Visceral leishmaniasis
<p>Antiamoebic and antigiardiasis medicines</p> <p>Oral &gt; Liquid: 125 mg per 5 mL as sulfate</p> <p>Oral &gt; Solid: 250 mg as sulfate</p>	Amoebiasis

## Pegaspargase

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral &gt; General injections &gt; IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection</p>	Lymphoid leukaemia, not elsewhere classified

## Pegylated interferon alfa (2a)

Section	Indications
<p>Medicines for hepatitis C &gt; Other antivirals for hepatitis C</p> <p>Parenteral &gt; General injections &gt; SC: 180 µg in vial; 180 µg in prefilled syringe</p>	Chronic hepatitis C

## Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

## Pembrolizumab

Section	Indications
Immunomodulators	Therapeutic equivalent to nivolumab for Melanoma of skin

## Penicillamine

Section	Indications
Antidotes and other substances used in poisonings > Specific Oral > Solid: 250 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 250 mg	Rheumatoid arthritis, serology unspecified

## Pentamidine

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 200 mg tablet; 300 mg tablet	Pneumocystosis
Medicines for the treatment of 1st stage African trypanosomiasis Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	African trypanosomiasis

## Permethrin

Section	Indications
Dermatological medicines > Scabicides and pediculicides Local > Topical > Lotion: 1%	Pediculosis corporis
Local > Topical > Cream: 5%	Pediculosis capitis
	Scabies

## Pertussis vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against pertussis alone

## Pertuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

## Phenobarbital

Section	Indications
Antiseizure medicines Oral > Liquid: 15 mg per 5 mL Oral > Solid: 15 to 100 mg Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)	Epilepsy or seizures Status epilepticus

## Phenoxyethylpenicillin

Section	Indications
Access group antibiotics Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 250 mg (as potassium salt) tablet Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	First choice Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Other indications Bacterial infection of unspecified site

## Phenytoin

Section	Indications
<p>Antiseizure medicines</p> <p>Oral &gt; Liquid: 30 mg per 5 mL (phenytoin)</p> <p>Parenteral &gt; General injections &gt; unspecified: 50 mg per mL in vial (phenytoin sodium)</p> <p>Oral &gt; Solid &gt; tablet: 50 mg (phenytoin) (chewable)</p> <p>Oral &gt; Solid &gt; dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)</p>	Epilepsy or seizures

## Phytomenadione

Section	Indications
<p>Medicines affecting coagulation</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule</p> <p>Oral &gt; Solid: 10 mg tablet</p>	<p>Haemorrhagic disorder due to other specified circulating anticoagulants</p> <p>Haemorrhagic or haematological disorders of fetus or newborn</p>

## Pilocarpine

Section	Indications
<p>Ophthalmological preparations &gt; Miotics and antiglaucoma medicines</p> <p>Local &gt; Ophthalmological &gt; Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)</p>	<p>Acute angle closure with pupillary block</p> <p>Ocular hypertension</p> <p>Primary open-angle glaucoma</p>

## Piperacillin + tazobactam

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection</p>	<p>First choice</p> <p>Peritoneal abscess (severe)</p> <p>Neutropenia (high-risk)</p> <p>Peritonitis (severe)</p> <p>Other specified pneumonia (Hospital-acquired pneumonia)</p>

## Platelets

Section	Indications
<p>Blood and blood components</p> <p>Parenteral &gt; General injections &gt; IV:</p>	Blood transfusion without reported diagnosis

## Plazomicin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg per 10 mL (Injection)	Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i>

## Pneumococcal vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

## Podophyllotoxin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to <i>podophyllum resin</i> for  <b>Anogenital warts</b>  Therapeutic equivalent to <i>podophyllum resin</i> for  <b>Plantar warts</b>

## Podophyllum resin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Solution: 10 to 25%	<b>Anogenital warts</b> <b>Plantar warts</b>

## Poliomyelitis vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against poliomyelitis

## Polygeline

Section	Indications
Plasma substitutes	Therapeutic equivalent to <b>dextran 70</b> for
Parenteral > General injections > IV: 3.5% injectable solution	<b>Hypovolaemia</b>
Parenteral > General injections > IV: 3.5% in solution	<b>Hypovolaemia</b>

## Polymyxins

Section	Indications
Reserve group antibiotics	<b>Other specified bacterial diseases</b>

## Potassium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Oral Oral > Liquid: powder for solution	<b>Hypokalaemia</b>
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)	<b>Hypokalaemia</b>

## Potassium ferric hexacyanoferrate

Section	Indications
Antidotes and other substances used in poisonings > Specific Oral > Solid: Powder for oral administration	<b>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</b>

## Potassium iodide

Section	Indications
Antifungal medicines Local > Topical > Solution: Saturated solution	<b>Sporotrichosis</b>
Thyroid hormones and antithyroid medicines Oral > Solid: 60 mg	<b>Thyrotoxicosis</b>

## Potassium permanganate

Section	Indications
Dermatological medicines > Anti-infective medicines Local > Topical > Solution: aqueous solution: 1:10 000	Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo

## Povidone iodine

Section	Indications
Antiseptics Local > Topical > Solution: 10% (equivalent to 1% available iodine)	Povidone iodine

## Pralidoxime

Section	Indications
Antidotes and other substances used in poisonings > Specific	Exposure to or harmful effects of undetermined intent of pesticides

## Pramipexole

Section	Indications
Antiseizure medicines Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 mg extended-release	Parkinson disease

## Pravastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis

## Praziquantel

### Section

Antischistosomals and other antitrematode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

### Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Diphyllobothriasis

Hymenolepiasis

Cysticercosis of central nervous system

## Precipitated sulfur

### Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Ointment:

### Indications

Therapeutic equivalent to **benzyl benzoate** for

Pthiriasis

Therapeutic equivalent to **benzyl benzoate** for

Pediculosis corporis

Therapeutic equivalent to **benzyl benzoate** for

Pediculosis capitis

Therapeutic equivalent to **benzyl benzoate** for

Scabies

## Prednisolone

Section	Indications
Hormones and antihormones	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Liquid: 5 mg per mL	Plasma cell myeloma
Oral > Solid: 5 mg; 25 mg	Follicular lymphoma
	Lymphoid leukaemia, not elsewhere classified
	Malignant neoplasms of prostate
	Chronic lymphocytic leukaemia or small lymphocytic lymphoma
	Hodgkin lymphoma
	Diffuse large B-cell lymphomas
	Burkitt lymphoma including Burkitt leukaemia
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive
	Langerhans cell histiocytosis
Anti-inflammatory medicines	Therapeutic equivalent to hydrocortisone for
Local > Rectal > Retention enema:	Crohn disease site
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)	Crohn disease site
	Ulcerative colitis
Antiallergics and medicines used in anaphylaxis	Allergic or hypersensitivity conditions of unspecified type
Oral > Liquid: 5 mg per mL	
Oral > Solid: 5 mg; 25 mg	
Ophthalmological preparations > Anti-inflammatory agents	Scleritis
Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)	Anterior uveitis

## Prednisone

Section	Indications
Hormones and antihormones	<p>Therapeutic equivalent to prednisolone for</p> <p>Plasma cell myeloma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Follicular lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Lymphoid leukaemia, not elsewhere classified</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Malignant neoplasms of prostate</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Hodgkin lymphoma</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Diffuse large B-cell lymphomas</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Anaplastic large cell lymphoma, ALK-negative</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>
	<p>Therapeutic equivalent to prednisolone for</p> <p>Langerhans cell histiocytosis</p>
Antiallergics and medicines used in anaphylaxis	<p>Therapeutic equivalent to prednisolone for</p> <p>Allergic or hypersensitivity conditions of unspecified type</p>

## Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant Mycobacterium tuberculosis

## Primaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)	<p>Malaria due to Plasmodium ovale</p> <p>Malaria due to Plasmodium vivax</p>

## Probenecid

Section	Indications
Medicines used to treat gout Oral > Solid: 500 mg	Gout

## Procainamide

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride) Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)	Cardiac arrhythmia

## Procaine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	First choice Congenital syphilis [children] Second choice Syphilis

## Procarbazine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg (as hydrochloride)	Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma

## Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

## Proguanil

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 100 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

## Promethazine

Section	Indications
<p>Antiemetic medicines</p> <p>Oral &gt; Liquid: 5 mg per 5 mL (hydrochloride)</p> <p>Oral &gt; Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)</p> <p>Parenteral &gt; General injections &gt; unspecified: 25 mg per mL in 2 mL ampoule</p>	Nausea or vomiting

## Propanol

Section	Indications
<p>Antiseptics</p>	Therapeutic equivalent to ethanol for Denatured alcohol

## Propofol

Section	Indications
<p>General anaesthetics and oxygen &gt; Injectable medicines</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg per mL; 20 mg per mL</p>	Anaesthetics and therapeutic gases

## Propranolol

Section	Indications
<p>Antihypertensive medicines</p> <p>Oral &gt; Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</p>	Essential hypertension
<p>Antianginal medicines</p> <p>Parenteral &gt; General injections &gt; IV: 1 mg in 1 mL ampoule (hydrochloride)</p>	Angina pectoris
<p>Oral &gt; Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</p>	
<p>Antiarrhythmic medicines</p> <p>Parenteral &gt; General injections &gt; IV: 1 mg in 1 mL ampoule (hydrochloride)</p>	Cardiac arrhythmia
<p>Oral &gt; Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</p>	
<p>Antimigraine medicines &gt; For prophylaxis</p> <p>Oral &gt; Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)</p>	Migraine

## Propylthiouracil

Section	Indications
<p>Thyroid hormones and antithyroid medicines</p> <p>Oral &gt; Solid: 50 mg</p>	Thyrotoxicosis

## Prostaglandin E1

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

## Prostaglandin E2

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 1 mg per mL	Therapeutic equivalent to prostaglandin E1 for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

## Protamine sulfate

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule	Haemorrhagic disorder due to other specified circulating anticoagulants

## Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis

## Pyrantel

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)	Ascariasis Enterobiasis Trichuriasis Hookworm diseases

## Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg	Tuberculosis

## Pyridostigmine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)  Oral > Solid: 60 mg (pyridostigmine bromide)	Myasthenia gravis

## Pyridoxine

Section	Indications
Vitamins and minerals Oral > Solid: 25 mg (hydrochloride)	Vitamin B6 deficiency  Sideroblastic anaemia  Other specified polyneuropathy

## Pyrimethamine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 25 mg	Toxoplasmosis

## Quinidine

Section	Indications
Antiarrhythmic medicines Oral > Solid: 200 mg (sulfate)	Cardiac arrhythmia

## Quinine

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)  Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)	Malaria due to Plasmodium falciparum

## Rabies vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against rabies

## Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Liquid: 100 mg granules for oral suspension Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ranibizumab

Section	Indications
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations	Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age related macular degeneration

## Ranitidine

Section	Indications
Antiulcer medicines Oral > Liquid: 75 mg per 5 mL (as hydrochloride) Oral > Solid: 150 mg (as hydrochloride) Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)	Gastro-oesophageal reflux disease Peptic ulcer, site unspecified

## Rasburicase

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution	Tumour lysis syndrome

## Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg	Chronic hepatitis C

## Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

## Red blood cells

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Retinol

Section	Indications
Vitamins and minerals Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule	Vitamin A deficiency

## Ribavirin

Section	Indications
Other antivirals Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

## Riboflavin

Section	Indications
Vitamins and minerals Oral > Solid: 5 mg	Vitamin B2 deficiency

## Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

## Rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Liquid: 20 mg per mL	Other specified tuberculosis
Oral > Solid: 150 mg; 300 mg	
PARENTERAL > General injections > IV: 600 mg in vial powder for injection	
Antileprosy medicines	Leprosy
Oral > Liquid: 20 mg per mL	
Oral > Solid: 150 mg; 300 mg	

## Rifapentine

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid: 150 mg tablet; 300 mg tablet	Latent tuberculosis

## Risdiplam

Section	Indications
Medicines for diseases of the nervous system	Spinal muscular atrophy
Oral > Liquid: 0.75 mg per mL powder for oral liquid	

## Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Rituximab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas
Medicines for multiple sclerosis Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial	Multiple sclerosis

## Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <b>dabigatran</b> for <b>Venous thromboembolism</b>
	Therapeutic equivalent to <b>dabigatran</b> for <b>Other specified atrial fibrillation</b>

## Ropinirole

Section	Indications
Antiseizure medicines	<b>Parkinson disease</b>

## Rotavirus vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	<b>Need for immunization against certain single viral diseases</b>

## Rubella vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	<b>Need for immunization against rubella alone</b>

## Salbutamol

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)	<b>Chronic obstructive pulmonary disease</b>
Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler	<b>Asthma</b>
Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers	

## Salicylic acid

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Solution: 5%	Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

## Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Selenium sulfide

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Suspension: 2% detergent-based	Seborrhoeic dermatitis Pityriasis versicolor

## Senna

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 7.5 mg per 5 mL oral liquid	Palliative care
Laxatives Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)	Constipation

## Sevoflurane

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation > liquid:	Anaesthetics and therapeutic gases

## Silver diamine fluoride

Section	Indications
Dental medicines and preparations Local > Dental > Solution: 38% w/v	Dental caries

## Silver nitrate

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Solution (eye drops): 1%	Neonatal conjunctivitis or dacryocystitis

## Silver sulfadiazine

Section	Indications
Dermatological medicines > Anti-infective medicines Local > Topical > Cream: 1%	Burns

## Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 150 mg	Chronic hepatitis C

## Simvastatin

Section	Indications
Lipid-lowering agents Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg	Mixed hyperlipidaemia Coronary atherosclerosis
Medicines for endocrine disorders Oral > Solid: 20 mg	Polycystic ovary syndrome

## Smallpox vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

## Snake antivenom

Section	Indications
Immunologics > Sera, immunoglobulins and monoclonal antibodies	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium calcium edetate

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

## Sodium hydrogen carbonate

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)	Acidosis

## Sodium nitrite

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium nitroprusside

Section	Indications
Antihypertensive medicines Parenteral > General injections > IV: 50 mg in ampoule powder for infusion	Hypertensive crisis

## Sodium stibogluconate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

## Sodium thiosulfate

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Solution: 15%	Pityriasis versicolor
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 400 mg; 200 mg	Chronic hepatitis C

## Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet	Chronic hepatitis C

## Spectinomycin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choice Gonococcal infection
	Other indications Bacterial infection of unspecified site

## Spironolactone

Section	Indications
Medicines used in heart failure Oral > Solid: 25 mg	Heart failure
Diuretics Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL Oral > Solid: 25 mg	Oedema Ascites

## Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 5 mg per 5 mL powder for oral solution Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Streptokinase

Section	Indications
Thrombolytic medicines Parenteral > General injections > IV: 1.5 million IU in vial powder for injection	Acute myocardial infarction

## Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

## Succimer

Section	Indications
Antidotes and other substances used in poisonings > Specific Oral > Solid: 100 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sulfacetamide

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Ointment: 10% (sodium salt)	Other specified conjunctivitis

## Sulfadiazine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 500 mg	Toxoplasmosis
Anti-infective medicines Oral > Solid: 500 mg Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)	Bacterial infection of unspecified site

## Sulfadimidine

Section	Indications
Anti-infective medicines	Bacterial infection of unspecified site
Oral > Liquid: 500 mg per 5 mL	
Oral > Solid: 500 mg	
Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)	

## Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For curative treatment	Malaria due to Plasmodium falciparum
Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium vivax
Antimalarial medicines > For chemoprevention	Malaria due to Plasmodium falciparum
Oral > Solid: 500 mg + 25 mg tablet	Malaria
Oral > Solid: 250 mg + 12.5 mg tablet	

## Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics	Bacterial infection of unspecified site
Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule	
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid	
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet	
Antipneumocystosis and antitoxoplasmosis medicines	Pneumocystosis
Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule	
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid	
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet	
Oral > Solid > dispersible tablet: 100 mg + 20 mg	

## Sulfasalazine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs)	Rheumatoid arthritis, serology unspecified
Oral > Solid: 500 mg	
Anti-inflammatory medicines	Crohn disease site
Oral > Solid: 500 mg	
Local > Rectal > Suppository: 500 mg	Ulcerative colitis
Local > Rectal > Retention enema:	

## Sumatriptan

Section	Indications
Antimigraine medicines > For treatment of acute attack	Migraine
Oral > Solid: 50 mg	

## Suramin sodium

Section	Indications
Antifilarials	Filariasis
Parenteral > General injections > IV: 1 g in vial	
Medicines for the treatment of 1st stage African trypanosomiasis	African trypanosomiasis
Parenteral > General injections > IV: 1 g in vial	

## Surfactant

Section	Indications
Medicines administered to the neonate [c]	Respiratory distress syndrome of newborn
Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation	

## Suxamethonium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors	Muscle relaxants
Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial	

## Tacalcitol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type

## Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease  Parenteral > General injections > IV: 5 mg per mL in 1 mL vial  Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension  Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues

## Tamoxifen

Section	Indications
Hormones and antihormones  Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Other specified malignant neoplasms of breast Malignant neoplasms of breast

## Telmisartan + amlodipine

Section	Indications
Antihypertensive medicines  Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg	Essential hypertension

## Telmisartan + hydrochlorothiazide

Section	Indications
Antihypertensive medicines  Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg	Essential hypertension

## Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  Oral > Solid: 25 mg	Chronic hepatitis B

## Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

## Terbinafine

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Cream: 1% terbinafine hydrochloride Local > Topical > Ointment: 1% terbinafine hydrochloride	Fungal infection of the skin

## Terbutaline

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma

## Terizidone

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis

## Testosterone

Section	Indications
Androgens Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

## Tetanus antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > IM: 50000 IU in vial	Tetanus

## Tetanus vaccine

Section	Indications
Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against tetanus alone

## Tetracaine

Section	Indications
Ophthalmological preparations > Local anaesthetics Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)	Local anaesthetics

## Tetracycline

Section	Indications
Access group antibiotics Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)	Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma

## Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

## Thiamine

Section	Indications
Vitamins and minerals Oral > Solid: 50 mg (hydrochloride)	Vitamin B1 deficiency

## Thiopental

Section	Indications
General anaesthetics and oxygen > Injectable medicines	Therapeutic equivalent to propofol for Anaesthetics and therapeutic gases

## Tick-borne encephalitis vaccine

Section	Indications
Recommendations for certain regions All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against arthropod-borne viral encephalitis

## Tigecycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

## Timolol

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)	Primary open-angle glaucoma Ocular hypertension

## Tinidazole

Section	Indications
Antiamoebic and antigiardiasis medicines	Therapeutic equivalent to metronidazole for Amoebiasis

## Tioguanine

Section	Indications
Cytotoxic medicines Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

## Tiotropium bromide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Respiratory > Inhalation > dry powder: 18 µg capsule Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation	Chronic obstructive pulmonary disease

## Tisagenlecleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to <a href="#">axicabtagene ciloleucel</a> for Diffuse large B-cell lymphomas

## Tislelizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 10 mL	Malignant neoplasms of urinary tract Hodgkin lymphoma

## Tobramycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to <a href="#">gentamicin</a> for Other specified conjunctivitis
	Therapeutic equivalent to <a href="#">gentamicin</a> for Infectious blepharitis

## Tolbutamide

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 500 mg	Type 2 diabetes mellitus

## Torasemide

Section	Indications
Medicines used in heart failure	Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Heart failure</a>
Diuretics	Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Anuria or oliguria</a> Therapeutic equivalent to <a href="#">furosemide</a> for <a href="#">Oedema</a>

## Tramadol

Section	Indications
Opioid analgesics Oral > Liquid: 100 mg per mL (hydrochloride)  Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release  Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)	<a href="#">Chronic cancer pain</a>

## Trametinib

Section	Indications
Targeted therapies Oral > Solid: 0.5 mg; 2 mg	<a href="#">Other specified melanoma of skin</a>

## Tranexamic acid

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	<a href="#">Haemorrhage, not elsewhere classified</a>
Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	<a href="#">Postpartum haemorrhage</a>

## Trastuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

## Trastuzumab emtansine

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

## Triclabendazole

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Solid > tablet: 250 mg (scored)	Fascioliasis Paragonimiasis

## Trihexyphenidyl

Section	Indications
Antiseizure medicines Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)	Parkinson disease
Medicines for parkinsonism	Therapeutic equivalent to biperiden for Parkinson disease

## Trimethoprim

Section	Indications
Access group antibiotics Oral > Liquid: 50 mg per mL Oral > Solid: 100 mg; 200 mg	First choice Infectious cystitis

## Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin for <b>Malignant neoplasms of breast</b>
	Therapeutic equivalent to leuprorelin for <b>Malignant neoplasms of prostate</b>

## Tropicamide

Section	Indications
Diagnostic agents > Ophthalmic medicines Local > Ophthalmological > Solution (eye drops): 0.5%	<b>Cycloplegic drug</b>

## Tropisetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron for <b>Palliative care</b>
Antiemetic medicines	Therapeutic equivalent to ondansetron for <b>Nausea or vomiting</b>

## Tuberculin, purified protein derivative

Section	Indications
Immunologicals > Diagnostic agents Parenteral > Locoregional injections > Intradermal:	<b>Mycobacterial diseases</b>

## Tubocurarine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)	<b>Muscle relaxants</b>

## Typhoid vaccine

Section	Indications
Recommendations for some high-risk populations All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against typhoid-paratyphoid alone

## Ulipristal

Section	Indications
Oral hormonal contraceptives Oral > Solid: 30 mg tablet (ulipristal acetate)	Contact with health services for postcoital contraception

## Umeclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to <a href="#">tiotropium bromide</a> for <a href="#">Chronic obstructive pulmonary disease</a>

## Urea

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Cream: 10%; 5% Local > Topical > Ointment: 10%; 5%	<a href="#">Xerosis cutis or asteatosis</a>

## Valaciclovir

Section	Indications
Antiherpes medicines	Therapeutic equivalent to <a href="#">aciclovir</a> for <a href="#">Zoster</a> Therapeutic equivalent to <a href="#">aciclovir</a> for <a href="#">Varicella</a> Therapeutic equivalent to <a href="#">aciclovir</a> for <a href="#">Herpes simplex infections</a>

## Valganciclovir

Section	Indications
Other antivirals Oral > Liquid: 50 mg per mL powder for oral solution Oral > Solid: 450 mg Tablet	<a href="#">Cytomegaloviral retinitis</a>

## Valproic acid (sodium valproate)

Section	Indications
Antiseizure medicines	Epilepsy or seizures
Oral > Liquid: 200 mg per 5 mL	Status epilepticus
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)	
Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	
Medicines for bipolar disorders	Bipolar or related disorders
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	

## Vancomycin

Section	Indications
Watch group antibiotics	First choice
Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection	co-prescribed with ceftazidime
	Endophthalmitis
	co-prescribed with ceftriaxone
	Endophthalmitis
	Other indications
	Methicillin resistant <i>Staphylococcus aureus</i>

## Varenicline

Section	Indications
Medicines for nicotine use disorders	Nicotine dependence
Oral > Solid: 0.5 mg; 1 mg	

## Varicella vaccine

Section	Indications
Recommendations for immunization programmes with certain characteristics	Need for immunization against certain single viral diseases
All vaccines should comply with the WHO requirements for biological substances.	

## Vecuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)	Muscle relaxants

## Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

## Verapamil

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride) Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)	Supraventricular tachyarrhythmia
Antianginal medicines Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)	Angina pectoris

## Vinblastine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis

## Vincristine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral &gt; General injections &gt; IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)</p> <p>Parenteral &gt; General injections &gt; IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Follicular lymphoma</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Rhabdomyosarcoma primary site</p> <p>Hodgkin lymphoma</p> <p>Diffuse large B-cell lymphomas</p> <p>Retinoblastoma</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Langerhans cell histiocytosis</p>

## Vinorelbine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial</p> <p>Oral &gt; Solid: 20 mg; 30 mg; 80 mg</p>	<p>Other specified malignant neoplasms of bronchus or lung</p> <p>Other specified malignant neoplasms of breast</p> <p>Rhabdomyosarcoma primary site</p>

## Voriconazole

Section	Indications
<p>Antifungal medicines</p> <p>Parenteral &gt; General injections &gt; IV: 200 mg in vial powder for injection</p> <p>Oral &gt; Liquid: 40 mg per mL powder for oral liquid</p> <p>Oral &gt; Solid: 50 mg tablet; 200 mg tablet</p>	<p>Chronic pulmonary aspergillosis</p> <p>Invasive aspergillosis</p>

## Warfarin

Section	Indications
Medicines affecting coagulation Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)	Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation

## Water for injection

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule	Unspecified appropriateness of dosing or administration without injury or harm

## Whole blood

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Xylometazoline

Section	Indications
Ear, nose and throat medicines [c] Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL	Nasal congestion

## Yellow fever vaccine

Section	Indications
Recommendations for certain regions All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain single viral diseases

## Zanubrutinib

Section	Indications
Targeted therapies Oral > Solid: 80 mg	Mantle cell lymphoma

## Zidovudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection  Oral > Liquid: 50 mg per 5 mL  Oral > Solid: 250 mg capsule; 300 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Zinc sulfate

Section	Indications
Medicines for diarrhoea Oral > Solid: 20 mg	Diarrhoea

## Zoledronic acid

Section	Indications
Supportive medicines Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow